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Infection with Mycobacterium tuberculosis is characterised by diverse 
outcomes; the majority of infected individuals remain well and yet others 
develop disease ranging from Jimited pulmonary tuberculosis to severe 
disseminated disease. The reasons for this diverse outcome are poorly 
understood, but host factors are thought to play an important role. In 
particular, a genetic component to susceptibility to tuberculosis has been 
proposed. 
An important clue was the description of a group of Maltese children with an 
unusual susceptibility to progressive non-tuberculous mycobacterial 
infections. These patients showed defective tumor necrosis factor (TNF) 
production in response to endotoxin and a failure to upregulate TNF 
production in response to interferon gamma as well as diminished interferon 
gamma production during T -cell proliferation. They were found to lack 
expression of the interferon gamma receptor ligand-binding chain (IFN-yR1) 
on their cell surfaces due to a single point substitution resulting in a truncated 
protein. Since then other defects in the type 1 cytokine pathway leading to 
susceptibility to non-tuberculous mycobacteria, as well as to tuberculosis, 
have been described in rare isolated cases. From these findings, the 
hypothesis arose that less severe mutations in such pathways might 
individually, or in combination, lead to increased susceptibility to tuberculosis 
in the general population. 
The following study forms part of a larger multi-centre collaboration, which 
aims to better understand the genetic basis of susceptibility to mycobacterial 
infection by addressing this hypothesis. The approach taken has been the 
recruitment and immuno-phenotyping of a large group of children with 
tuberculosis as well as control subjects. Candidate genes, of the type 1 
cytokine pathways being investigated, include interferon gamma, interleukin­
12 and their receptors and TNF. The focus of the study described in this 











for DNA sequence alterations in the TNF and TNFR1 genes. The individuals 
in this cohort were selected on the basis of their whole blood stimulation 
assays, where either high or low levels of TNF in response to non-specific 
stimulatory factors, were the determining criteria. It was assumed that these 
two phenotypic groupings would be enriched for gene variants contributing to 
the TNF responses recorded in the stimulation assays. Once identified, these 
polymorph isms would be screened for frequencies in the broader patient and 
control groupings and assessed for any association with susceptibility to 
tuberculosis. This study was considered important in attempting to explain 
which genes and their polymorph isms are involved in determining the high 













Screening of the human tumor necrosis factor (TNF) gene and its 
receptor 1 (TNFR1) gene for DNA alterations and the subsequent 
investigation of these and an IL12 p40 polymorphism for an association 
with paediatric tuberculosis 
Netanya Lampel 
MSc. thesis, Department of Paediatrics, University of Cape Town 
Tuberculosis is a chronic infection caused by Mycobacterium tuberculosis. 
The cytokine, tumor necrosis factor (TNF), has been shown to be important in 
controlling tuberculosis infection in both the mouse model and in human 
disease. Variation in TNF production between individuals is thought to be 
genetically determined. Genetic deficiencies in this and related cytokine 
pathways have been shown to predispose to mycobacterial infection. 
The study reported in this thesis has analysed the TNF gene and its type 1 
receptor gene (TNFR1) in a selected cohort of 71 subjects, who produce high 
or low levels of tumor necrosi  factor by in vitro assay. This was done in an 
attempt to determine a genetic basis for this difference. Children with a history 
of tuberculosis as well as healthy control children were included. The 
polymorphism screening method employed in this study was single stranded 
conformational polymorphism analysis. Once a polymorphism was detected, 
cycle sequencing was carried out. Ten polymorph isms involving nine single 
base substitutions and one single base insertion, induding four novel 
changes, were identified in the TNF gene. One polymorphism occurred within 
a Sp1 binding site and another within an Ap2 binding site on the promoter. 
Ten polymorph isms, of which four were novel, were identified in the TNFR1 
gene. Of these ten, one polymorphism was a two-basepair deletion while the 
rest were single base substitutions. One polymorphism in the coding region 











One previously identified polymorphism in the interleukin-12 p40 gene, +1188 
A~C, as well as the TNF -307 G~A polymorphism, were investigated for an 
association with paediatric tuberculosis. Genotyping of the TNF -307. G~A 
polymorphism, carried out using the Amplification Refractory Mutation 
System, was expanded to a cohort of 276 subjects, including 148 patients and 
128 controls. Genotyping of the interleukin-12 p40 + 1188 A~C polymorphism 
was carried out by Taq/ restriction enzyme analysis and expanded to a cohort 
of 281 subjects, including 156 patients and 125 controls. 
Allele frequencies were compared between the control and patient cohorts by 
means of a Chi-squared test. No significant differences in the distribution of 
the TNF -307 or interleukin-12 p40 +1188 polymorphismS were found 
between the patient and control subjects (P=O.B and P=0.3, respectively). 
Neither of these polymorphisms is associated with paediatric tuberculosis in 
an African population. Time constraints prevented screening of the entire 
patient and control cohorts for associations of the novel polymorph isms 
identified by this study with paediatric tuberculosis. This, as well as the 
















Tuberculosis (TB) is a chronic infection caused by Mycobacterium 
tuberculosis. Annually, about two million people worldwide die from TB 
infection while an estimated eight million new cases occur (Algood et al. 2003; 
Flynn 2004). TB is usually transmitted by inhalation of aerosolised bacilli 
produced during coughing by an infected individual, after which it may 
disseminate from the lungs throughout the body. Only about 10 percent of 
individuals who are infected develop clinical disease, with the remainder 
developing either sterilizing immunity or latent infection. Latent infection can 
progress to active TB if immunosuppression occurs (Mohan et al. 2001; 
Nunez Martinez 2001; Fenhalls et al. 2002; Algood et al. 2003). 
Immunosuppression could occur due to age, corticosteroids, malnutrition and 
human immunodeficiency virus (HIV) infection as well as other factors (Flynn 
2004). Fortunately, people infected with latent TB are not contagious. 
1.1.1 Paediatric tuberculosis 
The World Health Organisation (WHO) has estimated that there are 1.2 
million cases of TB in children every year, with about 450 000 dying annually 
from the disease. As many as 40% of all reported TB cases are paediatric in 
developing countries, with as many as 10% of all hospital admissions of 
children due to TB and 10% of paediatric deaths due to TB. It is therefore 
important and necessary to study and control paediatric TB. Childhood TB is a 
public health measure of recent transmission of M. tuberculosis from an 
infected adult. Ma:ny adults who develop reactivation and contagious TB 
probably acquired the infection during childhood (Starke 2003). 
Paediatric TB varies from adult TB in many characteristics. Children are more 












and the disease can be crippling in children (Smith et at 1997; Starke 2003). 
Childhood TB results mostly from primary infection rather than from the 
reactivation of latent infection. It is a Significant cause of mortality as children 
are more likely than adults to develop active TB after infection with M. 
tuberculosis. About 15-43% of children compared to 5% of adults develop TB 
after primary infection (Aubert-Pivert et al. 2000). TB infection in children is 
usually acquired from an infectious adult or adolescent living in the same 
household. About 5-10% of children infected with tuberculosis will go on to 
develop 'progressive primary TB', where the primary infection site enlarges 
and undergoes caseous necrosis, resulting in a cavity (Shewchuck and Reed 
2002). 
1.1.2 Overview of host defences against tuberculosis 
Mycobacteria are inhaled in droplet nuclei past the protective mechanical 
barriers of the upper respiratory tract and reach the alveoli where the initial 
infection takes place (Smith et al. 1997). The alveolar macrophage is the 
primary host cell for M. tuberculosis and is the first fine of defence against 
infection in the lung (Keane et al. 1997; Balcewicz-Sablinska et a!. 1998). The 
mycobacteria are phagocytosed by these macrophages following which they 
persist and replicate within the macrophage, or are killed by these cells; the 
latter occurring through mechanisms that include reactive oxygen and 
nitrogen intermediates within lysosomal compartments, hydrolytic enzymes 
within the phagolysosome and activation of apoptotic pathways. If the bacteria 
manage to evade these mechanisms and continue to replicate. dissemination 
throughout the body via the lymphatics and the bloodstream could occur, 
thereby creating new sites of infection in other tissues. Macrophages also 
elaborate cytokines such as TNF, interleukin-12 (1L12) and chemokines in 
response to mycobacteria and these can act together to orchestrate the 
specific and non-specific host defences against tuberculosis. TNF is 
considered to be important in this initia1 host response; however it 
paradoxically appears to contribute to some of the pathological features seen 












The host defence against intracellular pathogens such as mycobacteria is 
dependent on effective cell-mediated immunity (CMI), which results in the 
local containment of pathogens inside well-organised granulomatous lesions 
in the lungs (Ottenhoff et at 2002). The development of this antigen-specific 
host response is dependent on a co-ordinated interplay between T -cells, 
macrophages and other antigen presenting cells (APC's) such as dendritic 
cells. The T -cell-mediated immune response to microorganisms starts with the 
intracellular processing of protein and subsequent antigen presentation to T­
cells by dendritic cells and macrophages in the context of major 
histocompatibility (MHC) molecules. APC's. especially the dendritic cells, 
migrate from the lung to the regional lymph node where they elaborate 
cytokines and present mycobacterial antigens to CD4+ T -cells (Smith et at 
1997). 
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Figure 1.1. The cytokine interactions between the T or NK lymphocyte and the 
infected macrophage. Macrophages produce IL12, which leads to the T-cell 
production of TNF and IFNy. IFNy stimulates the macrophages to produce TNF and 











The T-cells then elaborate key effector cytokines such as interferon-gamma 
(lFNy) and TNF (Smith et al. 1997) (fig. 1.1). This provides signals to attract 
further T -lymphocytes and monocytes to the site of infection where a 
granuloma is formed. The activation of infected macrophages by type 1 
cytokines, such as IFNy, is the principle effector mechanism of CMI, leading to 
killing of intracellular mycobacteria. Antigen-specific type 1 helper T-cells (Th1 
cells) and natural killer cells (NK cells) produce the IFNy protein which then 
binds to IFNy-receptor R 1/R2 complexes which are 90 kD and 62 kD 
respectively. These R1/R2 complexes are found at the macrophage surface 
(Otten hoff et at 2002). Their activation by IFNy results in increased production 
of interleukin-1 (IL 1) and TNF, enhanced antigen presentation and increased 
production of nitric oxide and reactive-oxygen intermediates (Newport et at 
1996). 
Another cytokine, IL 12, regulates the production of IFNy by Th1 and NK cells. 
IL 12 is a heterodimer consisting of 40 kO and 35 kO subunits (p40 and p35). It 
is produced by antigen-presenting cells, which include macrophages, 
monocytes and dendritic cells, after the activation of Toll-like receptors on 
these ceUs by bacterial ligands. IL 12 is therefore a link between adaptive and 
innate immunity. IL12 binds to IL12 receptor JH (100 kD) and fJ2 (130 kO) 
complexes at the surface of Th1 and NK cells (Ottenhoff et al. 2002). 
Signalling through TNF receptor 1 (TNFR1) is thought to play an essential role 
in regulating granuloma formation (Roach et at 2002). TNF is expressed at 
the site of human T6 and is considered to be crucial in determining the course 
of the disease (Engele et al. 2002). Granulomas contain the bacilli in a low 
nutrient and oxygen environment, which prevents their spread (Algood et al. 
2003). The process of granuloma formation is dependent on the activation of 
mycobacteria-reactive T-Iymphocytes, especially CD4+ and CDS+ T-cells that 
secrete IFNy (Roach et al. 2002). The granuloma increases in size as more 
and more mononuclear leukocytes, are recruited with various zones becoming 
apparent within the granuloma. As the infected macrophages die and the 












otherwise known as caseous necrosis. Myeloid cells, multinucleated giant 
cells and lymphocytes surround this area of caseous necrosis. The lesion can 
go on to either calcify or liquefy. M. tuberculosis replicates exponentially within 
the liquefied necrotic lesions and if the lesion ruptures into an airway. the 
replicating bacteria can reseed other areas of the lung or the body or they can 
be expelled into the environment and infect another host (Fen halls et al. 
2002). 
The protective immune response in humans against M. tuberculosis remains 
inadequately defined. IFNy, together with TNF, activates anti-mycobacterial 
microbicidal mechanisms in murine macrophages (Bean et al. 1999; Mohan et 
al. 2001; Otten hoff et al. 2002; Smith et al. 2002; Wagner et al. 2002). There 
are conflicting reports of a similar role for IFNy in Mycobacterium tuberculosis 
infected human macrophages, although it can affect the growth of 
Mycobacterium bovis bacille Calmette-Guerin (BCG) in human macrophages 
(Otten hoff et at 2002). It is not well understood how the bacilli can persist in 
the face of a strong immune response (Algood et al. 2003). 
The high mortality rates in childhood TB may be due to the relative immaturity 
of early non-specific immune responses in children. The recruitment of 
activated cells to primary and post-primary sites of infection may be delayed 
in children due to defective chemotaxis of monocytes and macrophages. The 
development of an antigen-specific response may be delayed by inefficient 
presentation to naiVe T -cells. This results in low levels of production of IFNy 
and TNF, which may in turn limit the activation of macrophages and result in 
higher bacterial loads at the site of infection. Therefore, childhood TB is likely 
to involve defects in the immune defence against tuberculosis (Aubert-Pivert 
et al. 2000). 
Cytokine profiles in bronchoalveolar lavage (BAl) samples from children 
infected with TB reveal that TNF mRNA's are more abundant in children with 
primary TB than in children with other pulmonary diseases. High levels ofll1 0 












by IL10. This likely explains the poor granuloma formation and 
haematogenous dissemination occurring in miliary TB. The recurrent 
dissemination of M. tuberculosis in this form of TB is probably as a result of 
difficulty in containing the primary infection in granulomas (Aubert-Pivert et at. 
2000). 
1.1.3 Evidence of a genetic basis for susceptibility to tuberculosis 
Evidence that genetic factors play a role in susceptibility to TB comes from 
twin studies, familial clustering of TB infection, racial differences in incidence, 
and animal models (Newport et at 1996; Stein et at 2003). Environmental 
conditions such as poverty, malnutrition, overcrowding and stress do not fully 
explain an increased susceptibility of some populations over others (Stein et 
at 2003). Twin studies have provided convincing evidence that inherited 
susceptibility is a risk factor for tuberculosis with the degree of concordance 
for tuberculosis being higher for monozygotic than dizygotic twins (Comstock 
1978; Cooke and Hill 2001; Jepson et a!. 2001). A study carried out by Stead 
et al. (1990) revealed that both the incidence and prevalence of TB among 
residents in nursing homes and inmates in prisons in Arkansas were twice as 
high in blacks as in whites. This difference is usually attributed to social 
factors such as overcrowding and poverty; however this study looked at 
blacks and whites living in the same social conditions, i.e. in nursing homes 
and prisons and strongly suggests the existence of heritable differences 
between individuals and groups with respect to the immune defence system 
against TB. 
A genome-wide search for tuberculosis-susceptibility genes in Africans, using 
linkage analysis and common ancestry using microsatellite (CAM) mapping, 
revealed evidence for these on chromosomes 15q and Xq. No single marker 
was strongly linked to disease suggesting that there is no single TB­
susceptibility gene Africans (Bellamy et al. 2000). The Angelman syndrome 
gene, UBE3A, is found the region on chromosome 15 of suggestive linkage 
identified above. This gene encodes a ubiquitin ligase that has been found to 












which in turn plays a role in transducing T-cell receptor signalling in T -cells. 
Therefore, alterations in UBE3A could affect the T-cell response to M. 
tuberculosis and thus further analysis to evaluate this gene as a major 
susceptibility gene for TB is warranted (Cervino et at 2002). 
Genetic deficiencies in the IFNy receptor and IL12 and its receptor have 
pointed to critical roles for these cytokines in the protective immune response 
against infection by non-tuberculous, poorly pathogenic mycobacteria. 
(Newport et al. 1996; Engele et al. 2002; Otten hoff et al. 2002). A number of 
different genes that play a role in the type 1 cytokine cascade have been 
investigated for coding sequence alterations that may increase susceptibility 
or resistance to TB infection. These include the genes for IL12p40, IL 12Rp1, 
IFNyR1. IFNyR2 and STAT1 (lFNy-associated signal transducer and activator 
of transcription). The degree of impairment in function was found to correlate 
overall with the severity of the clinical, immunological and histopathological 
phenotypes analysed. Individuals with complete IFNyR deficiency have 
suffered from a severe and fatal outcome after infection with mycobacteria. 
Partial deficiency in IFNyR, partial deficiency in STAT1 or complete or partial 
deficiency in IL12RJ31 have resulted in individuals developing milder less 
severe infections with possibly milder histopathological phenotypes. 
Deficiency in IL 12RJ31 is associated with a milder phenotype, possibly due to 
low levels of production of IFNy. independent of IL12R. The contribution of 
particular genes could vary depending on a population's background, 
including previous infection pressure (Otten hoff et at 2002). For example, 
homozygosity for the IFNy +874 T allele has been found to be associated with 
susceptibility to TB in Sicilians and in South Africans, but not in Malawians. 
Similarly, variants in manhose-binding lectin (MBL2) may be protective 
against meningeal TB in Cape Coloureds but this is not the case in The 
Gambia or Malawi. Therefore, genetic susceptibility to TB in Africans is 
polygenic (Fitness et al. 2004). 
Definition of the disease phenotype has been a limiting factor in previous 












pulmonary disease, but can affect nearly all organs. In addition, active 
disease may present at any time after infection, i.e. a person's current TB 
status does not reflect a long-term disease risk (Stein et at 2003). 
Since only a relatively small percentage of those infected with M. tuberculosis 
develop clinical disease, infection is necessary, but not enough, to cause 
clinical TB disease on its own. Although a number of studies such as those 
described above support genetic factors in human susceptibility to TBt no 
model for genetic susceptibility is accepted and this may in part be due to the 
heterogeneity of disease expression. Therefore, intermediate immune 
phenotypes of TB could be analysed as they may be more directly connected 
to gene expression. Intermediate traits for TBt including IFNy, TNF and 
transforming growth factor 13 (TGFI3) secretion in stimulated peripheral blood 
mononuclear cells (PBMC's) were analysed in 177 index-case subjects and 
their household contacts in a Ugandan community. TNF was found to have 
the highest heritability (68%), which suggests  strong genetic component in 
susceptibility to TB. Therefore further study of TNF with respect to TB 
susceptibility is warranted (Stein et al. 2003). This provides a good reason for 
TNF as our choice as a candidate gene. 
Susceptibility to mycobacterial infection is likely to be a complex, multifactorial 
and multigenic trait to which a number of genetic pathways contribute. The 
contribution of a particular genetic pathway to disease susceptibility could 
vary according to the stage of infection. For example, the genetic pathways 
that control susceptibility to primary infection with M. tuberculosis may not 
correlate entirely with those that control susceptibility to re-activation of latent 
TB. The classification of susceptibility-associated alleles in host genes will be 
beneficial in understanding the mechanisms of protection against TB infection 
as well as providing new targets for preventive or post-infection .intervention 














TNF (previously known as TNFa or cachetin) is a pleiotropic inflammatory 
cytokine produced by a number of different celt types (Balcewicz-Sablinska et 
al. 1998; Knight and Kwiatkowski 1999; Keane et at 2001; Roach et al. 2002). 
It is produced mainly by macrophages in response to stimuli that activate toll­
like receptors and can also be expressed by activated T -cells, B-cells and NK 
cells (Ehlers 2003). Keratinocytes, astrocytes, macroglial cells, smooth 
muscle cells, intestinal paneth cells, mesangial cells and tumor cells also 
produce TNF (Makhatadze 1998). TNF, belonging to the TNF ligand family 
(Makhatadze 1998), is one of the first immunological mediators to appear 
when infection is encountered. TNF production does not usually necessitate 
previous immunological exposure; the macrophages of a non-immune 
individual that encounter a pathogen, release copious amounts of TNF within 
several hours (Knight and Kwiatkowski 1999). 
Human TNF has membrane-bound (26 kO) and secreted forms, which are 
both biologically active. The membrane-bound form is cleaved by a 
metalloprotease called disintegrin (TNF converting enzyme), to a secreted 
monomer (17 kO) of which three associate to form the biologically active 
extracellular form of TNF (Ruuts and Sedgwick 1999; Pfeffer 2003). TNF can 
induce a broad spectrum of biologic effects, including fever, tissue injury and 
alveolar macrophage activation (Balcewicz-Sablinska et at 1998; Keane et at 
2001; Roach et at 2002). TNF also plays a role in lipid metabolism, 
coagulation, insulin resistance (OMIM 191160) and apoptosis and in the 
endothelial trapping of Circulating immune cells by upregulating adhesion 
molecules such as adhesion molecule 1 (lCAM-1) (Bean et at 1999; Knight 
and Kwiatkowski 1999). It has therefore commonly been thought to mediate 
the deleterious effects of TB, which include fever, weight loss and tissue 
necrosis. TNF has been implicated in the pathogenesis of a number of human 
diseases including cancer, rheumatoid arthritis, diabetes, osteoporosis, 














stages of infection in order to control replication of bacilli within the major 
organs. The sUbcutaneous injection of TNF alone prevented the occurrence of 
necrosis in these major organs, but did not cure the inflammatory lesions 
present in these organs. This study therefore provides evidence that a lack of 
TNF leads to serious infection or death in mice infected with TB (Kaneko et al. 
1999). 
A more severe picture of non-containrnent and fatal disease occurs in the 
TNFR1 deficient mouse infected with BCG, therefore TNF signalling through 
its type 1 receptor is indispensable in the control of BCG infection. TNF­
deficient mice had significantly delayed BCG clearance in the liver and spleen 
and its growth was uncontrolled in the lungs. There was a higher mortality rate 
ofTNFR1-deficient mice compared to TNF deficient mice, which suggests that 
Iymphotoxin alpha (LTa) signalling through TNFR1 could playa role in 
mycobacterial clearance. In addition, the TNF-deficient mice had reduced 
adhesion molecules such as ICAM-1 and CD11 b and absent CD11 c in 
granulomas studied in the liver when compared to wildtype mice, indicating 
that TNF is important for the expression of adhesion molecules. The formation 
of mycobactericidal granulomata has been shown to be ICAM-1 dependent. 
TNF deficient mice, reconstituted with wildtype bone marrow, were able to 
control mycobacterial growth to a similar extent as wildtype controls therefore 
TNF derived from hemopoietic cells rather than from mesenchymal origin is 
sufficient for a normal host response to infection with BCG (Jacobs et al. 2000 
(a». 
Animal studies have provided evidence that the local pulmonary host 
response is a crucial part of the immune response to M. tuberculosis, even 
though the extrapulmonary immune response is important for eventual control 
of infection. To directly study the role of TNF in local host responses in the 
lung, Smith et al. (2002) generated and characterised transgenic mice with 
local pulmonary inhibition of TNF. They concluded that TNF inhibition in the 
lungs impairs the host response to M. tuberculosis infection and that the 












intrapulmonary defect in its activity. TNF facilitates bacterial clearance and 
appears to be an important modulator of lung ini1ammation. Inhibition of TNF 
activity in the lungs during the early stage of infection results in persistent 
inflammation and immune activation, due to an increase in the expression of 
proinflammatory cytokines such as IL1, IL6, IL18 and IFNy, with an increase in 
mycobacterial tissue burden leading to exaggerated pathology and lung injury 
(Smith et at 2002). 
1.2.1.2 Evidence from the mouse model of 'reactivation 
tuberculosis' 
Evidence that TNF is essential in preventing disease reactivation was 
provided in a study carried out by Mohan et at (2001) in which they used 
persistent M. tuberculosis infection in mice as a model for latent TB. The 
neutralisation of TNF, 6 to 8 months post-infection with M. tuberculosis 
(laboratory mice normally live just over 2 ye rs), was initiated by injecting 
MP6-XT22 (rat anti-murine TNF hybridoma) twice weekly for the duration of 
the experiment. Control mice received normal rat immunoglobulin G (lgG) 
following the same schedule. TNF neutralisation resulted in disease 
reactivation associated with an increase in bacterial numbers. which peaked 
at 20 days after MP6-XT22 treatment and not thereafter. The mice 
succumbed, with a mean survival time of 59 ± 22 days, after MP6-XT22 
treatment. The TNF-neutraHsed mice displayed defective recruitment and/or 
migration of inflammatory cells, as indicated by much less apparent lymphoid 
aggregates in the MP6-XT22-treated mice 3 weeks post TNF neutralisation. In 
addition, the expression of nitric oxide synthase 2 (NOS2) was attenuated in 
the MP6-XT22 treated mice, compared to NOS2 levels in IgG-treated mice. 
These data suggest that attenuated NOS2 expression contributes to some 
extent to reactivation of infection in the TNF-neutralised mice (Mohan et al. 
2001). 
Evidence that TNF is important in granuloma formation is provided in this 












common link to the unfavourable disease outcome associated with chronic 
persistence and reactivation of TB and TNF deficiency in acute TB. The 
results of this study suggest that TNF is critical in trafficking of immune cells to 
infectious foci, thereby promoting the formation and maintenance of well­
organised granulomata, which control disease and prevent reactivation 
(Mohan et al. 2001). 
1.2.1.3 Evidence from human tuberculosis 
Evidence from studies in mice supporting a role for TNF in the defence 
against infection has been discussed in this thesis. Since no human subject 
has been recorded with a genetic deficiency of TNF. we rely on evidence from 
studies of the effect of anti-TNF treatment in humans. There are two drugs 
that specifically target TNF. namely infliximab and etanercept (Ehlers 2003). 
Infliximab ;s a chimeric monoclonal antibody. which binds with high affinity to 
both monomeric and trimeric TNF, and is widely used in the treatment of 
rheumatoid arthritis (RA) and Crohn's disease (CD) (Keane et al. 2001; 
Wagner et al. 2002; Ehlers 2003). Infliximab therapy reduces inflammatory 
infiltrate and TNF production in the intestinal segments involved in CD (Nunez 
Martinez et al. 2001). The biological effect of infliximab persists for up to two 
months (Keane et al. 2001). Infliximab neutralises the inflammatory effect of 
TNF by binding to its soluble subunit and with transmembranous TNF so that 
it may not interact with its receptor (Nunez Martinez et at 2001; Sandborn 
2003). It forms stable complexes with soluble as well as transmembrane TNF 
and rarely releases them once bound (Ehlers 2003). It also causes lysis of 
TNF-producing cells via compliment fixation and antibody-dependent 
cytotOxicity and leads to T-cell apoptosis (Sandborn 2003). 
There are now multiple reports of cases of TB following treatment with 
infliximab. The first case occurred during a clinical trial (Keane et al. 2001). 
The same authors subsequently investigated all reports of T8 after infliximab 
therapy through the MedWatch spontaneous reporting system of the Food 












treated with infliximab when compared with background rates. Most of the 70 
cases of tuberculosis associated with infliximab therapy reported in this study 
were from countries with low incidence rates of TB, less than 20 cases per 
100 000 population per year. The background rate of TB in patients with RA in 
the US is 6.2 cases per 100000 population per year and the estimated rate of 
TB among patients receiving infliximab for RA in the US is 24.4 cases per 100 
000 population per year (Keane et al. 2001). The data obtained in the study 
by Keane et al. (2001) suggested an association with the use of anti-TNF 
therapy, such as infliximab or etanercept, and reactivation TB. 
Of the 70 reports of TB after infliximab treatment, 56 percent of patients had 
extrapulmonary disease and 24 percent had disseminated disease. These 
forms of tuberculosis are usually associated with immunosuppression, such 
as in HIV infection. Generally only 18 percent of cases of TB not associated 
with immunosuppression manifest as extrapulmonary disease while 
disseminated disease usually accounts for less than 2 percent (Keane et at 
2001). 
In other isolated reports. Lim et al. (2002) describe the reactivation of latent 
TBin a patient treated with infliximab for uveitis. The patient's T -cells were 
able to produce IFNy and he had no other known immunodeficiency. The 
clinical course of disease described, was consistent with an association 
between infliximab a d reactivation TB (Lim et al. 2002). Nunez Martinez et 
al. (2001) describe, a patient who developed reactivation TB after infliximab 
therapy. 
Most of the reported cases of TB in patients treated with infliximab occurred in 
countries with a low incidence of TB, as infliximab is expensive and rarely 
available in poor countries where TB is more frequent. It is likely that most of 
these patients had reactivation disease given the low background incidences 
of TB. It is feasible that patients receiving treatment with infliximab are 
susceptible to disease after primary infection and reinfection with M. 











Etanercept is a dimeric fusion protein consisting of the extracellular ligand 
domain of human TNFR2 and the Fc region of IgG1. It neutralises soluble 
TNF and l T c;(. (infliximab cannot bind to LT<><) (Ehlers 2003). Myers et at 
(2002) describe a patient diagnosed with osteoarticular TB shortly after 
receiving treatment with etanercept (Myers et al. 2002). Etanercept has a 
more limited function than infliximab and neutralises soluble TNF but does not 
bind to transmembrane TNF (Sandborn 2003). It traps TNF/lT (J( at sites 
where they are abundant and then releases them at sites of lower 
concentrations (Ehlers 2003). 
TNF alone does not activate antimycobacterial activity in murine or human 
macrophages, therefore the reactivation of TB in patients treated with 
infliximab is most likely not due to a loss of antimycobacterial activity, but 
rather reflects the disintegration of granulomata, thereby allowing dormant 
mycobacteria to convert into metabolically active and destructive pathogens 
(Engele et al. 2002). 
1.2.2 The specific role of TNF in the host defence against T8 
The evidence described above clearly shows the importance of TNF in 
controlling TB infection in both the mouse model and in human disease. There 
are a number of proposed mechanisms whereby TNF exerts this activity, 
including macrophage activation, granuloma formation, apoptosis and the 
activation of neutrophils. 
1.2.2.1 Macrophage activation 
Macrophages are stimulated upon infection with M. tuberculosis, and 
subsequently produce TNF and other cytokines to initiate an inflammatory 
response. T -cells are then recruited to the site of infection where they are 
needed for the creation of granulomas. TNF, together with IFNy produced by 












intermediates and nitric oxide synthase, compounds with mycobactericidal 
activity (Bean et al. 1999; Mohan et al. 2001; Smith et al. 2002; Wagner et al. 
2002). Therefore, both IFNy and TNF are likely to be significant in controlling 
mycobacterial infection and granuloma formation (Jacobs et at 2000 (b». 
However, the role of TNF is not as clear as that of IFNy in human TB infection 
(Smith et al. 2002; Wagner et al. 2002). 
TNF has opposite effects on the growth of virulent (H37Rv and M. bovis, 
pathogenic in mice) and attenuated (H37Ra, heat-killed M. tuberculosis, and 
BeG) mycobacteria. Virulent mycobacteria seem to have developed efficient 
evasion mechanisms for protection against the attack of the host immune 
system, while attenuated strains are susceptible to the activation of the host 
cell by TNF. Virulent strains can activate more alveolar macrophages for TNF 
production than attenuated strains. Exogenous TNF increases intracellular 
growth of virulent mycobacterial strains in alveolar macrophages and in 
contrast, limits prOliferation of attenuated mycobacterial strains. Possible 
mechanisms as to how TNF interferes with the antibacterial effector 
mechanisms of human alveolar macrophages include deprivation of 
intracellular iron, modulation of the maturity of cells, regulation of 
chemokine/cytokine release and induction of apoptosis of infected cells 
(Engele et al. 2002). 
1.2.2.2 Granuloma formation 
Even early granulomas are not maintained when TNF signalling is absent, 
resulting in their diSintegration, causing the death of mice infected with 
mycobacteria. Lung specimens from TB patients typically show well-formed 
granulomata, while the lung specimen from a TB patient that had taken 
infliximab showed a lack of granuloma formation with lymphoid inflammation 
(Keane et at 2001). TNF probably regulates the inflammatory response by 
maintaining the viability of activated macrophages at infection sites. In the 












destruction becomes apparent, therefore TNFR1 is required for modulation of 
the T-cell response (Ehlers 2003) (table 1.1). 
The pattern of cytokine production in the human lung granuloma was studied 
in five patients with pulmonary TB. All the patients produced TNF mRNA, with 
three of the patients displaying detectable levels of IFNy and IL4 mRNA. Two 
patients were found to be negative for IL4 mRNA and positive for IFNy mRNA. 
These latter two patients expressed lower levels of TNF mRNA and had more 
necrotic granulomas than the three patients who were positive for both IFNy 
and IL4. Therefore it appears that TNF positively corre1ates with IL4 gene 
expression and negatively with caseous necrosis (Fenhalls et al. 2000). 
Table 1.1 The effect of blocking TNF or LT during experimental 
mycobacterial infections in mice (Adapted from Ehlers (2003» 
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1.2.2.3 Apoptosis 
M. tuberculosis infection induces TNF-dependent macrophage apoptosis 
(Balcewicz-Sablim~ka et al. 1998). Since TB is' a chronic infection, apoptosis 
may favour the host by reducing the potential for macrophages to provide 
sanctuaries for mycobacteria. Further, during apoptosis, IL1f3 and nitric oxide 
are released, both ofwhich play an important role in controlling mycobacteria. 
Conversely, the killing of alveolar macrophages could benefit the 












extravasation and migration of neutrophils to the site. The neutrophils 
phagocytose the tubercle bacilli in the presence of TNF secreted by the 
macrophages. These mechanisms are operative to sterilise limited challenges 
by mycobacteria but can be overwhelmed, with some individuals being able to 
resist infection longer than others (Kisich et al. 2002). 
1.2.3 TNF signalling 
The binding of a ligand, usually a microbial product, to a cell surface Toll 
receptor initiates the process of TNF production. This Toll receptor then 
stimulates a signal transduction pathway that adivates NFf<.B transcription 
fadors, which then enter nuclei and induce the transcription of genes 
associated with inflammation, including TNF. The production of TNF and other 
inflammatory cytokines acts to stimulate other inflammatory cells, which then 
release cytokines and consequently amplify the immune response 
(Suryaprasad and Prindiville 2003). 
Human TNF is a polypeptide hormone that consists of three non-glycosylated 
subunits. The hormone is made initially as a prohormone that has 76 
additional amino acid residues attached to the N·terminus, creating a 
hydrophobic domain that anchors the molecule to the cell surface 
(Makhatadze 1998). TNF is then proteolytically cleaved to remove these 
additional residues to produce a soluble 17 kD form (Makhatadze 1998; 
Hajeer and Hutchinson 2001). 
TNF elicits its cellular responses through its interaction with two distinct 
receptors, the 55 kD, type 1 tumor necrosis receptor (TNFR1, p55, CD120a) 
and the 75 kO, type 2 tumor necrosis receptor (TNFR2, p75, C0120b) 
(Balcewicz-Sablinska et al. 1998; Papadakis and Targan 2000; Keane et at 
2001). Both these receptors bind TNF and L T €X (previously known as TNFI3) 
specifically and with high affinity (OMIM 191190). TNFR1 and TNFR2 are 
initially cell surface membrane proteins, which can then be cleaved to become 












part of the TNF-nerve growth factor (NGF) receptor family and are expressed 
on almost all somatic cells (Makhatadze 1998). TNFR1 is expressed on many 
cell types, while TNFR2 is expressed mainly on leukocytes and endothelial 
cells (Papadakis and Targan 2000). TNFR2 has a higher affinity for TNF, 
especially at lower concentrations of TNF (Hajeer and Hutchinson 2001). 
The TNFR1 gene encodes a protein consisting of 455 amino acids. The signal 
transmembrane domain consists of about 23 amino acids, while the 
extracellular domain is made up of 171 residues and the cytoplasmic domain 
of 221 residues. The first 35 amino acids are hydrophobic and represent a 
signal sequence (Gray et al .. 1990). The extracellular ligand-binding domain is 
composed of four repeats of cysteine-rich 40-amino acid motifs with each 
interrupted by an intron (Fuchs et al. 1992). The ligand-binding domain is from 
residues 77 to 114. There are two extracellular, cysteine-rich subdomains 
(CR01 and CR02) each consisting of three disulphide bonds and structurally 
conserved regions (Banner et al. 1993). 
The TNFR1 and TNFR2 receptors are both shed from the cell surface in a 
soluble form, which aid in regulating TNF function. These soluble receptors 
neutralise TNF activity by competing with membrane-bound receptors and 
also stabilise TNF and prevent its degradation (Hajeer and Hutchinson 2001). 
The extracellular domains of the two receptors are very similar in structure, 
while their intracellular domains seem to be unrelated (OMIM 191190), which 
is consistent with the observation that the two receptors carry out different 
functions in vivo and activate different signalling cascades (Bazzoni and 
Beutler 1996). 
The intracellular region of TNFR1 has a death domain (~O), consisting of 
about 70 amino acids, which is required for Signalling apoptosis and activating 
NFKB (McDermott et al. 1999; Papadakis and Targan 2000). A 60 kO silencer 
of death domains (5000) maintains TNFR1 in an inactive monomeric state 
by inhibiting the ligand-independent aggregation of TNFR1 cytoplasmic 












homotrimers to TNFR1 and TNFR2, thereby eliciting their biological functions 
(Bopst et al. 2001). TNFR1 preferentially binds soluble TNF, while TNFR2 
predominantly binds the membrane-associated form (Papadakis and Targan 
2000). 
TNF homotrimers bind to TNFR1's extracellular domain. Signalling is induced 
by the aggregation of the membrane receptors after the SODO dissociates 
from the cytoplasmic DO of the receptor. The adaptor protein TRADD (TNFR­
associated death domain) is then recruited by the aggregated DO signalling 
complex (Papadakis and Targan 2000; Chen and GoeddeI2002). The TNFR1 
signalling complex is formed when TRADD recruits FADD (Fas-associated 
death domain), TRAF (TNFR-associated factor 2) and RIP (receptor 
interacting protein), which then activates signalling cascades that lead to 
apoptosis, NFK.B activation as well as JNKlSAPK (c-Jun N-terminal 
kinase/stress-activated protein kinase) (fig. 1.2) (Papadakis and Targan 
2000). 
Figure 1.2. The TNF signal transduction pathway. TNF binds to TNFR1 with the 












adaptor proteins TRAF2, FADD and RIP. These then recruit other proteins, which 
become activated and initiate downstream events including apoptosis, NF'KB and 
JNK activation (Chen and Goeddel 2002). 
TNF signalling through TNFR2 involves recruitment of TRAF2. TRAF1 and c­
lAP's (cellular inhibitor of apoptosis proteins) to the intracellular domain of the 
receptor. This complex then mediates NFKB and JNK activation through 
TRAF2 (Papadakis and Targan 2000). KO mice for the TNFR1 gene are more 
susceptible to challenge with intracellular bacterial pathogens than TNFR2 
knockouts or wildtype mice, which suggests that the proinflammatory effects 
of TNF are mediated predominantly through the p55 receptor (McDermott et 
al. 1999). 





The TNF gene encodes the TNF cytokine and is located within the highly 
polymorphic major histocompatibility complex (MHC) on the short arm of 
chromosome 6, (6p21.3). It is about 3 kilobase pairs in length. comprises 4 
exons and 3 introns and codes for a precursor product of 230 amino acids 
and a mature product of 157 amino acids (Nedwin etal. 1985). 
The synthesis of TNF is tightly controlled at many different levels due to its 
potentially harmful effects. This control is partially achieved by a number of 
negative feedback systems (Jongeneel 1995). Circulating TNF levels are 
regulated at a number of stages, including gene transcription, post­
transcription control of mRNA stability, cleavage of the membrane form to 
produce the soluble form and receptor expression (Hajeer and Hutchinson 
·2001). Bacterial endotoxin and lipopolysaccharide (LPS) are strong inducers 
of TNF transcription. The TNF promoter is a 1.2 kilobase region that has a 












These include NF!(.S binding sites (GGGGACTTTCC), a GC box or Sp1 
binding site, a Y-box, a cAMP-responsive element-binding (CRES) protein 
binding site, AP-1, AP-2, Erg-1, H-APF-1, nuclear factor interleukin 6 (NF­
IL6), Oct-2, nuclear factor of activated T cells (NF-AT) and Ets binding sites. 
There are four possible binding sites for NFI'B. TNF expression is regulated 
by MHC class II ligands during transcription and translation (Makhatadze 
1998; Takashiba et al. 1993; Ye et a!. 2003). Evidence has shown that by 
blocking the action of NF \C. S alone, gene expression of TNF would be 
sufficiently inhibited (Ye et at 2003). The activation of TNF by different 
transcription factors is dependent on the cell type involved as well as the 
nature of stimulation (Ye et al. 2003). 
Studies in mice and subsequently in humans have confirmed the importance 
of promoter heterogeneity in the pathogenesis of disease (Suryaprasad and 
Prindiville 2003). There are a number of genetic variants in the human TNF 
promoter, including SNP's located at positions -1031, -863, -857, -851, 
-419, -376, -308, -238, -163, -49 and +70, +488 and +691 (intron 1) relative 
to the transcription start site as well as an insertion at position +70 and a 
deletion at position +691 (Hajeer and Hutchinson 2001; Bridges et a!. 2002). 
The 5' region of TNF is therefore highly polymorphic, with the 3' region being 
less so. Local TNF levels may be under the control of specific polymorph isms, 
while circulating TNFlevels may be under the control of a multifactorial 
regulatory process (Hajeer and Hutchinson 2001). 
Do any of these promoter polymorphisms influence gene expression? Several 
groups have addressed this question. For example, electrophoretic mobility 
shift assay (EMSA) as well as reporter gene analysis of the -863 C~A 
polymorphism revealed that NFKS (both p65-p50 and p50-p50 dimers) bind to 
this site, with the C~A substitution inhibiting p50-p50 binding. This may 
decrease the enhancer effect of NFKS in TNF activation (Udalova et al. 2000). 
The TNF -376 G~A polymorphism is situated in a region of multiple DNA­












TNF secretion is thought to be under the control of variable genetic elements 
within the MHC (Nadel et al. 1996). One such element has been described in 
the promoter region of TNF. This -308 G-+A SNP has been the most studied 
one, however different studies have produced conflicting results as to whether 
the -308 A allele does influence TNF transcription or not (Hajeer and 
Hutchinson 2001). The -308 A allele has been shown to be a much stronger 
transcriptional activator than the more common -308 G allele using reporter 
gene assays (Wilson et al. 1997). 
This bi-atlelic, -308, polymorphism within the TNF promoter region has been 
associated with malaria severity in Gambian children, where those 
homozygous for the -308 A allele have shown almost a fourfold increase in 
risk of contracting cerebral malaria and a sevenfold increase in the likelihood 
of death or the development of serious neurological consequences. 
Possession of the -308 A allele may be associated with higher constitutive 
and inducible levels of transcription than that for the -308 G allele, thereby 
determining susceptibility to cerebral malaria (McGuire et al. 1994). The 
-308 A allele also appears to be associated with an increased severity of 
meningococcal disease in children, who have a genetic predisposition to 
secrete higher levels of TNF following invasion by meningococci. However it 
does not predispose individuals to acquiring invasive meningococcal disease 
(Nadel et al. 1996). Although much research has been done on the TNF gene, 
no definitive disease-related TNF polymorphism has been characterised 
(Ruuls and Sedgwick 1999). 
1.3.2 TNFR1 
The tumor necrosis factor receptor is part of a superfamily of receptors. The 
TNFR1 gene encodes the 55 kD TNFR1 protein and is expressed in all 
nucleated cells. This gene is located on chromosome 12p13 and contains 10 
exons (Fuchs et al. 1992; Bridges et al. 2002). The promoter region of this 












appears to be active in gene transcription. Promoter activity seems to be 
limited to a CT-rich region located from -207 to -385, which has high 
homology to the murine p55 TNFR1 promoter. The promoter region 
resembles that of a housekeeping gene as transcription is driven from multiple 
start points (tsp) and there are no TATA or CAAT box motifs. There are two 
closely located TCC repeat motifs upstream from the furthest upstream tsp, 
which are also present in the EGF (epidermal growth factor) receptor 
promoter. The sequence upstream from -385 has an inhibitory effect on 
promoter activity. The putative negative regulatory element is located between 
-663 and -809 (Kemper and Wallach 1993). 
A number of genetic variants have been identified in this gene and in its 
promoter region, however their effects on transcription or protein function are 
largely unknown (Bridges et a!. 2002). Three SNP's lie in the 5' promoter 
region, -609 G~T, -580 A~G and -383 A~C. There is an A~C SNP at 
position -383 relative to the translation start site. The -383 A~C SNP can be 
detected by Bgnl restriction enzyme digestion where the C allele abolishes the 
cutting site. A significantly increased frequency of the -383 C allele was seen 
in young-onset (25.6% heterozygotes) (P= 0.0056) and adult-onset diabetes 
(24% heterozygotes) (P=0.015) patients when compared with controls (11% 
heterozygotes). The C allele was also found to be associated with higher 
expression of TNFR1 than the A allele in v;tro (Nishimura et a!. 2003). 
The -609 T allele creates a Bst4CI restriction site (Allen et at 2001). The 
allele frequencies of the three promoter polymorph isms were very different 
between healthy Afl;can Americans and healthy Caucasians; 0.13 versus 0.42 
for -609 T, 0.49 versus 0 for -580 G and 0.14 versus 0 for -383 C (Bridges et 
al. 2002). No association of the -609 polymorphism with disease course or 
severity was found in multiple sclerosis (MS) (Weinshenker et at 1999) or in 












A polymorphism in exon 1, P12P, has been identified by Loetscher et al. 
(1990). A novel missense substitution, resulting in an amino acid change of 
proline to leucine at codon 75 has been identified in a study of eighty-four 
African Americans and seventy-four Caucasians (Martin et al. 2003). A 100% 
of Caucasians were found to be wildtype (CCG, proline), while 85% of African 
Americans were wildtype, 15% were heterozygotes (CIT) and 1 % were 
homozygous (CTG, leucine) for the substituted base (T) (Martin et al. 2003). 
Several missense mutations in the coding region of TNFR1 have been 
identified in autoinflammatory syndromes (Bridges et al. 2002) (Table 1.2). 
TNFR1 gene mutations 
Mutations in the extracellular domain, that lead to decreased shedding and 
increased cell surface expression of TNFR1, have been found to be linked to 
dominantly inherited inflammatory syndromes (Hajeer and Hutchinson 2001). 
Six different missense mutations were identified in TNFR1 in seven families of 
varied ethnic backgrounds that suffered from periodic fever syndromes. The 
name TRAPS (TNF receptor-associated periodic syndromes) best describes 
this class of autoinflammatory disease. The mutations were present in the 
heterozygous state. Five of these mutations disrupted conserved extracellular 
disulphide bonds (McDermott et al. 1999). 
Table 1.2 Reported mutations of the TNFR1 gene 
DNA alteration Published 
H22Y, exon 2 Aksentijevich et al. (2001) 
C30R, exon 2 McDermott et al. (1999) 
C30S, exon 2 Dode et al. (2000) 
i C33Y, exon 2 McDermott et al. (1999) 
C33G, exon 2 Aksentijevich et al. (2001) 
P46L, exon 3 Aksentijevich et al. (2001) 
T50M, exon 3 McDermott et al. (1999) 












C88R, exon 4 McDermott et al. (1999) 
C88Y, exon 4 
Splice site mutation, 
G~A, intron 3 
McDermott et al. (1999) 
Aksentijevich et al. (2001) 
R92Q, exon 4 Aksentijevich et al. (2001) 
R92P, exon 4 Aganna et al. (2001) 
The P46L and R92Q mutations were identified in patients as well as at a low 
frequency in controls implying that both these mutations are probably low 
penetrance mutations rather than benign polymorph isms. The observation of 
multiple mutations at specific residues suggests a critical role for these sites. 
(Aksentijevich et al. 2001). 
The R92P mutation was found to segregate with TRAPS in a two-generation, 
6-member, Dutch family. This mutation was also found in two unaffected 
members of this family, which suggests that it has reduced penetrance 
(Aganna et al. 2001). A polymorphism in intron 6 was found to have no 
association with disease when studied in CAD by restriction digestion with 
BstEII (Allen et al. 2001). All of the 16 TRAPS mutations identified so far are 
clustered within the first two cysteine-rich extracellular subdomains (CRD1 
and CRD2) (Aksentijevich et al. 2001). 
1.41L 12 
One of the inter/eukin-12 p40 gene polymorph isms, 3'UTR A~C, has also 
been examined in this thesis. The reason being that it was recently shown to 
be in association with type 1 diabetes (T1D). Interleukin-12 (IL 12p70) (5q31­
33) is a proinflammatory cytokine composed of two disulphide-bonded 
polypeptide chains, 35 kD and 40 kD, which are encoded by the IL 12A and 
IL 12B genes respectively. IL 12p40 may form homodimers and is expressed 
mainly in dendritic cells, macrophages and monocytes while IL 12p35 is 
expressed constitutively in many cell types. IL12 plays an important role in the 












CD4+ T-cells and NK cells to differentiate towards Th1 cells, which are 
associated with cell-mediated immunity and secrete IFNy. IL12 is therefore 
likely to be important in the protective immunity against Mycobacterium 
tuberculosis infection (Huang et al. 2000; Ma et al. 2003). 
Due to the significant role that the p40 subunit has in the immune system, it is 
likely that genetic variants in the gene that encodes this cytokine may be key 
to causing immunoregulatory abnormalities. IL12 deficient individuals would 
probably occur rarely, however less severe DNA alterations in the subunit 
genes could interact with other DNA variants to predispose to resistance or 
susceptibility to infectious diseases or to autoimmunity (Huang et al. 2000). 
Mice KO experiments revealed that IL12 p35 -/- and p40 -/- mice are 
susceptible to M. tuberculosis infection. Inherited impairment of immunity to 
mycobacterial infection has been reported in individuals with rare founder 
mutations in the IL12B gene (Ma et al. 2003). 
1.4.1 A 3'UTR polymorphism of the IL12 p40 subunit 
Huang et al. (2000) identified an A-;C base change at position +1188, in the 
3'UTR of IL12p40, which results in the creation of a Taq1 site at this position. 
This polymorphism has been shown to be associated with susceptibility to 
multiple sclerosis (MS) and T1 D. The 3'UTR C allele is preferentially 
transmitted to T1 D patients and may therefore confer susceptibility or be in 
linkage disequilibrium with the disease-predisposing variant. The A allele may 
thus confer resistance to T1 D. Higher IL12 levels were found in the relatives 
of T1D probands. This increased IL12 may promote Th1 cells and exacerbate 
autoimmune destruction of !3-cells, resulting in T1 D as seen in NOD (non­
obese diabetic; spontaneously develop T1 D) mice (Morahan et al. 2001) on 
which studies have shown that administration of an antagonist to IL12 before 
the onset of insulitis results in the reduction of spontaneous and accelerated 












In a study by Ma et al. (2003), a total of 223 white individuals (106 with TB 
infection and 117 without TB infection) and 363 African Americans (186 with 
TB infection and 167 without TB infection) were genotyped at the IL12 p40 3' 
UTR. The C allele occurred at a lower frequency in white subjects (0.18) than 
in African American subjects (0.34) (P<0.001). This study failed to provide 
evidence for a significant association between this polymorphism and adult 
TB. The TOT (transmission disequilibrium test) analysis revealed that none of 
the 3' UTR alleles were preferentially transmitted to affected children, 
therefore it was concluded that the 3' UTR polymorphism has no effect, or a 
negligibly small effect on human susceptibility to TB. This polymorphism may 
therefore not be functional in IL 128 expression as previously thought, 
however this study had limited power and perhaps a further study with a 
larger sample size is necessary. 
1.5 AIMS IN SUMMARY 
The aims of this thesis can be summarised as follows: 
1. 	 To screen DNA from a select group of individuals, from a paediatric TB 
cohort, who show high and low whole blood TNF levels in in vitro 
stimulation tests using LPS as the mitogen. The screen was limited to 
the genes for TNF and TNFR1, with sequence alterations being 
detected by the single stranded conformational polymorphism (SSCP) 
technique and DNA sequencing. 
2. 	 To screen the entire cohort of patient and control samples for selected 
polymorphisms identified by SSCP. 
3. 	 To screen the entire cohort of patients and controls for the 3'UTR 














PATIENTS, MATERIALS AND METHODS 

2.1 OVERVIEW 
The subjects (n=71) examined in this study were drawn from a much larger 
patient and control cohort being assembled as part of a Well come 
Trust/Burroughs Wellcome (WT/BW) initiative. This program is now in the final 
year of its five-year initial funding and has the broad aim of establishing the 
genetic basis of resistance or susceptibility to Mycobacterium tuberculosis 
infection. It has concentrated on a candidate gene approach and has 
allocated different candidate genes for study to the different units involved in 
this multi-centre collaboration. including a unit here in Cape Town at Red 
Cross Children's Hospital, Imperial College, London and Stanford University. 
One of the candidate genes decided upon for the Cape Town unit included 
TNF as well as its receptor 1 (TNFR1) gene. It was decided that this thesis 
would concentrate on DNA screening of a group of selected patient and 
control subjects whose LPS stimulated white cells yielded either high or low 
TNF levels (within the upper and lower tertiles respectively). The assumption 
here was that this cohort would be enriched for polymorph isms impacting on 
TNF gene and protein expression and would be large enough to uncover 
polymorph isms of major biological importance in the South African population. 
The molecular methodology selected for this study included gene 
amplification by PCR primer sets, designed to amplify the promoters. coding 
regions and the 3' untranslated regions of each of the two genes. The primers 
were designed so that they overlapped the exon/intron boundaries in order to 
detect possible splice site variants and any variants in flanking intronic 
sequence. 
Following amplification, each PCR product was subjected to single stranded 












Electrophoresis system. The SSCP gels were treated with a silver stain in 
order to visualise DNA bands and determine any band shifts. Running 
conditions for the SSCP-PAGE were optimised to yield two bands for most 
PCR products. Approximately 43 PCR samples were run on each gel with 
band shifts being determined by comparative visual analysis. If a particular 
PCR fragment's banding pattern appeared to be different when compared to 
other apparently 'normal' banding patterns, which were more numerous on a 
typical gel, that sample was subjected to repeat PCR and electrophoresis. If 
the sample again showed the same altered banding pattern then the PCR 
product was further analysed by Big Dye® cycle sequencing. The resulting 
sequences were analysed using the NCBI BLAST search site where the 
sample sequences were compared against reference sequences in the 
database. Sequence variants that were novel, underwent repeat PCR and 
cycle sequencing for confirmation. 
One SNP detected in the SSCP study and the IL12 3'UTR SNP were selected 
for further evaluation of a possible association with M. tuberculosis infection. 
These were the TNF -307 G~A polymorphism and the +1188 A~C 
polymorphism, respectively. The frequencies of these polymorph isms in the 
control and patient cohorts were compared by Chi-squared analysis in order 
to determine the presence, or lack, of an association. 
2.2 SELECTION OF PATIENTS 
An existing wr/BW funded programme at the Red Cross Children's Hospital 
has been establishing a cohort of black and mixed ancestry children with TB 
as well as age-matched healthy controls since 2001. This programme recruits 
children with active TB as well as children with a past history of TB infection. 
In vitro immune phenotyping is conducted and DNA stored. Children are 12 
years of age or younger and selected for this study based on a clinical or 
laboratory diagnosis of TB and a negative test for HIV infection. Blood is taken 
during the acute stage of illness (in the case of patients) either before or 












after recovery. Whole blood stimulation is carried out on patient and control 
bloods. The blood is diluted 1 in 10 with RPMI. This is then stimulated with 
LPS (O.5ng/ml) overnight for 18 hours at 37°C with 5% CO2. TNF is then 
measured in culture supernatants by ELISA (Pharmingen Cytokine ELISA 
protocol, 2nd Ed, San Diego, CA, USA). 
For this thesis a total of 71 individuals from the above TB cohort were 
screened for sequence changes in the TNF and TNFR1 genes. A total of 40 
cases (26 with a past history of TB, 14 with active TB) and 31 control subjects 
were selected. Selection was based on TNF responses to LPS, with the upper 
and lower tertiles being selected for each group. In the control group, the cut­
off levels of TNF were >2500pg/ml (n=13) or <1000pg/ml (n=18). In the past 
history group, the levels were >2000pg/ml (n=12) or <1000pg/ml (n=14). 
Amongst those with active disease, cut-off levels were >3000pg/ml (n=3) or 
<750 pg/ml (n=11). The cases included those with TB meningitis, pulmonary 
TB, pleural TB and disseminated TB. 
2.3 MOLECULAR METHODOLOGY 
2.3.1 DNA isolation and storage 
DNA samples from the patients and controls were drawn from the DNA stock 
of the WT/BW project. These DNA stocks were derived from EDTA blood 
samples with the DNA being isolated according to the QIAmp ® DNA Blood 
MidikitlMaxikit protocol (Qiagen, Germany). DNA stocks were kept at -20°C 
for long-term storage. 
2.3.2 Polymerase chain reaction (PCR) 
PCR primers were designed by Susan Sullivan of the Wellcome Trust TB 
research group (Imperial College, London) (table 2.1 and table 2.2) and where 
necessary by this laboratory. Design criteria included a product size of 
approximately 350bp, a length between 19-24 bases and a GC+AT Tm of 
64°C. All the primers flanked the exon/intron boundaries in order to detect 












was included in every PCR run to rule out template or amplicon 
contamination. 
An additional control DNA, not taken from the TB cohort, was used to optimise 
each PCR primer pair. It was amplified with each primer set during PCR 
optimisation where different Taq polymerases and magnesium concentrations 
were tested and once the desired PCR product was obtained (as seen by 
agarose gel electrophoresis), the same PCR conditions were applied to the 71 
selected DNA samples for amplification. A number of different Taq 
polymerase preparations were utilised in this study. Taq polymerase 
(Promega) is normally used in the Cape Town research laboratory. Red Hot® 
DNA polymerase (ABgene) is a 'red' thermostable DNA polymerase. It 
contains Thermoprine Plus DNA polymerase, and contains an inert red dye to 
facilitate low volume pipetting and as an indicator for enzyme addition. This 
enzyme displays enhanced thermal stability at DNA denaturation 
temperatures. HotstarTaq® DNA polymerase (Qiagen) has been designed to 
provide 'hot-start' PCR for higher PCR specificity through the minimisation of 
non-specific amplification products, primer-dimers and background smears. It 
is well suited for amplification involving complex genomic or cDNA templates, 
very low-copy targets or multiplex primer pairs. It is inactive at ambient 
temperatures, which prevents the formation of misprimed products and 
primer-dimers at low temperatures. The enzyme is activated by a 95°C 
incubation step for 15 minutes. This polymerase often increases the yield of 
specific PCR product. 
We experienced some difficulties with the initial primer stocks as some primer 
pairs failed to amplify. These primers were checked for degradation by 
electrophoresis on a 10% sequencing gel (Sambrook et al. 1989) with silver 
staining (Caetano-Anolles and Gre~hoff 1994). Appendix A summarises the 
materials used for this troubleshooting procedure. The resulting gel is shown 












1 2 345 
Figure 2.1. A 10% sequencing gel of primers that failed to produce the required PCR 
product. All primers were supplied at a concentration of 2501J.M. Some primers 
produced no bands at all (lanes 3, 4, 5, 6, 8,11,12, 13, 14, 17,24,25,26) while 
others had multiple bands (1, 2, 7,9,15, 16,27,28,29), indicating that degradation 
had taken place. Lane 10 had no sample loaded. Other primers produced bands with 
different intensities to their corresponding primer partner such as the pair in lanes 19 
and 20. Primer bands were visualised by silver staining . What is interesting to note is 
that lanes 28 and 29 represent the forward and reverse primers, respectively, of a 
primer pair that amplified the target DNA, although there were multiple bands in 
these lanes and two main bands of different intensities. Perhaps some primer pairs 
are more sensitive to differing concentrations (although all stock concentrations 
prepared by the Wellcome Trust in the UK were assumed to be identical). Also, 
different levels of degradation may be tolerated until the primer no longer amplifies. 












The primer sequences and the Taq polymerases utilised for the screening of 
the TNF gene are summarised in table 2.1. 
Table 2.1 	Primers for the amplification of the TNF gene, including the 











p1 f: TGAAGCCCAA T AAACCTCTTTIC 
p1 r: CTGTGGTCACATCTCCCCAG 
353 59 HotstarTaq 
Promoter, 
part 2 
p2f: GGAA TGGGTT ACAGGAGACCT 
p2r: GTGAAA TCACCCCCGGGAA TT 
353 59 Red Hot 
Promoter, 
part 3 
p3f: TCAGAA TGAAAGAAGAGGGCCT 
p3r: CTGAACCCCGTCCCCA TGC 
370 59 Red Hot 
Promoter, 
part 4 
p4f: ATGGAGGCAA TAGGTTTIGAGG 
p4r: AGGGAGCGTCTGCTGGCTG 
353 59 HotstarTaq 
Promoter, 
part 5 
p5f: AT AT AAAGGCAGTTGTTGGCACA 
p5r: CAGAAGAGCGTGGTGGCGC 
353 59 HotstarTaq 
Exon 1 e1f: AAGCTGCCAGGCAGGTTCTC 
e1 r: GCACATCTTICACCCATCCCA 
352 59 HotstarTaq 
Exon 2+3 e2,3f: CCTCGATGTTAACCATTCTCCT 
e2,3r: AGCCCTCCAAGTTCCAAGACA 
354 59 HotstarTaq 
Exon 4 e4if: CTGACTCTCCTCTCCCTCTC 
e4ir: GACCCCTCCCAGAT AGATGG 
350 59 HotstarTaq 
Exon4 e4iif: AGAGGGGGCTGAGGCCAAG 
e4iir: GCCACACA nCCTGAATCCCA 
343 59 Red Hot 
3'UTR 3'1f: AGCAACAAGACCACCACTTCG 
3' 1r: CGGTCTCCCAAA T AAA T ACATTC 
384 59 Red Hot 
3'UTR 3'2f: CCCATGGAGCCAGCTCCCT 
3'2r: TTAA TTCCAAGAAGGAGACCATG 













The sequence of the TNF promoter and the peR primer sets for the 































Figure 2.2. The DNA sequence of the TNF promoter (GenBank NT _009759) . The 
sequences highlighted in blue refer to the forward and reverse primers for part 1, 
those in red refer to the primers for part 2, those in green to the primers for part 3, 
those in light blue to the primers for part 4, while those in yellow refer to the primers 
for part 5 of the promoter. The underlined and bolded A is the transcription start site 
and it is referred to as position +1 . The underlined and bolded ATG is the translation 
start site. 
All peR amplifications were carried out in a GeneAmp peR System 9700 (PE 
Applied Biosystems, USA). The final reaction volume was 25 III in 0.5 ml 
tubes (tables 2.3, 2.4, 2.5 and 2.6). The primer sequences and the Taq 













Table 2.2 Primers for the amplification of the TNFR1 gene, including the 
promoter, introns, exons and the 3'UTR 
Gene Primer Fragment Annealing Polymerase 
region 
Size (bp) temp (Ta) 
(0C) 
Promoter, p1 f: CGATGATCTGT AAGGTGAGTT AT 353 59 Red Hot 
part 1 
p1 r: CCCTCGTTITCTGCCCTGAC 
Promoter, p2f: TGAGGAA TGGCAGGCACCCA 352 59 HotstarTaq 
part 2 
p2r: CTGGGTTCCAA TTCAGAA TGCT 
Promoter, p3f: GTGTCCAAGACACATTCTT AGC 365 59 HotstarTaq 
part 3 
p3r: AGAAAA TTAAAGCAGAGAGGAGG 
Exon 1 e1f: CCCCTCCCACCTTCTCTCC 344 59 HotstarTaq + 
e1 r: GAAGGTGCCTCGCCCACCA 
Q-solution 
Exon 2 e2f: CT AAGCTTCCCATCCCTCCC 352 59 HotstarTaq 
e2r: CTGAAGTCTCT AGGAGAGGAG 
Exon 3 e3f: GTCTCTCCTGGGCTGGGA TT 349 59 HotstarTaq + 
e3r: TGCCCACACCCACCAGCCT 
Q-solution 
Exon 4 e4f: GTGGGTGCCTGTCT ATGTGC 349 59 HotstarTaq 
e4r: TGGCCTCAGGAGAGCTGCG 
Exon 5 e5f: ACCGTGCACCTCTCCTGTGA 350 59 HotstarTaq 
e5r: CCA TCCAGTGCCCAGCAGC 
Exon 6+7 e6,7f: TTCACCAGTGCCGTCTCTTCT 3S1 59 Red Hot 
e6,7r: CTCTCCCTCCCAAAGCCCC 
Exon S eSf: AAGCTCT ACTCCA TTGGTGAGT 373 59 HotstarTaq 
eSr: GGAGT AACTCTCTCA TTTCATCT 
Exon 9 e9f: TGTTGCGCCACCTTCTCTCTT 350 59 HotstarTaq 
e9r: CCAGCCTCCTCGTCTCCAG 
Exon 10 e10if: GACAGTGAGTTTCTCCCGCG 370 56 Red Hot + Q­
e10ir: GCTCCAGCGTGGCCTCGC 
solution 
Exon 10 e10iif: GCTGGCGACCTGGAGGCG 370 59 Red Hot + Q­
e10iir: GCCCACGGCGCACCTCTC 
solution 
The sequence of the TNFR1 promoter and the peR primer sets for the 



































Figure 2.3. The DNA sequence of the TNFR1 promoter (GenBank NT_009731). The 
sequences highlighted in blue refer to the forward and reverse primers for part 1, 
those in red refer to the forward and reverse primers for part 2, those in green refer to 
the forward and reverse primers for part 3 of the promoter, while those in light blue 
refer to the forward and reverse primers for exon 1. The underlined and bolded ATG 












Different PCR mixes were utilised for the different Taq polymerases used. 
These are detailed in tables 2.3, 2.4, 2.5 and 2.6. 
Table 2.3 Reaction mix for PCR amplification using Taq DNA 
polymerase * 
Reagent Stock conc. Volume Conc./Amt. 
DNA 100 ng/)ll 1 )ll 100ng 
Forward primer 10 )lM 1.25 )ll 0.5 )lM 
Reverse primer 10 )lM 1.25 )ll 0.5 )lM 
®
dNTP's (ABgene , 
Surrey, UK) 
2.5mM 2 )ll 200 )lM 
10X PCR buffer (Promega, 
Madison, WI, USA) 
10X 2.5 )ll 1X 
Magnesium (Mg:l+) (Promega, 
Madison, WI, USA) 
25mM 1.5 )ll 1.5 mM 
Promega Taq (Promega, 
Madison, WI, USA) 
5Ulvolume 0.13)l1 0.625U 
dH20 15.38 )ll 
Tota.1volume 25 )ll 
* Promega, Madison, WI , USA 
The amplification reaction was carried out in a GeneAmp PCR System 9700 
(PE Applied Biosystems, USA) using the following reaction conditions: 
1) initial denaturation - 94°C / 2 minutes for 1 cycle 
2) 30 cycles: denaturation - 94°C /30 seconds 

annealing - XoC* / 30 seconds 

elongation - 72°C / 30 seconds 

3) final step - 72°C /5 minutes for 1 cycle 












Table 2.4 Reaction mix for PCR amplification using Red Hot® DNA 
Polymerase * 
Reagent Stock conc. Volume Conc./Amt. 
DNA 100 ng/~1 1 ~I 100ng 
Forward primer 10 ~M 1.25 ~I 0.5 ~M 
Reverse primer 10 ~M 1.25 ~I 0.5 ~M 
dNTP's (ABgene®, 2.5mM 2 ~I 200 ~M 
Surrey, UK) 
10X PCR buffer (ABgene ®, 10X 2.5 ~I 1X 
Surrey, UK) 
Magnesium (Mg2+) (ABgene®, 25mM 1.5 ~I 1.5 mM 
Surrey, UK) 
® ®
Red Hot Taq (ABgene , 5U/volume 0.13 ~I 0.625U 
Surrey, UK) 
dH20 15.38 ~I 
Total volume 25 ~I 
* ABgene®, Surrey, UK 
The amplification reaction was carried out in a GeneAmp PCR System 9700 
(PE Applied Biosystems, USA) using the following reaction conditions: 
1) initial denaturation - 94°C 12 minutes for 1 cycle 
2) 28 cycles: denaturation - 94°C 130 seconds 

annealing - XoC* I 30 seconds 

elongation - 72°C I 30 seconds 

3) final step - 72°C 15 minutes for 1 cycle 












Table 2.5 Reaction mix for PCR amplification using Red Hot® DNA 






DNA 100 ng/~1 1 III 100ng 
Forward primer 10 IlM 1.25 III 0.5 ~M 
Reverse primer 10 IlM 1.25 III 0.5 ~M 
®
dNTP's (ABgene , 
Surrey, UK) 
2.5mM 2 III 200 IlM 
10X PCR buffer (ABgene®, 
Surrey, UK) 
10X 2.5 ~I 1X 
Magnesium (Mg2+) (ABgene®, 
Surrey, UK) 
25mM 1.5 ~I 1.5mM 
® ®
Red Hot Taq (ABgene , 
Surrey, UK) and JumpStart™ 
Antibody (Sigma-Aldrich, GmbH, 
Germany) 
5U/volume 0.75 ~I 0.625U 
dH20 14.75 ~I 
Total volume 25 ~I 
.1 ABgene®, Surrey, UK 
.2 Sigma-Aldrich, GmbH, Germany 
The amplification reaction was carried out in a GeneAmp PCR System 9700 
(PE Applied Biosystems, USA) using the following reaction conditions: 
1) initial denaturation - 94°C 12 minutes for 1 cycle 
2) 28 cycles: denaturation - 94°C I 30 seconds 

annealing - XoC· I 30 seconds 

elongation - 72°C I 30 seconds 

3) final step - 72°C I 5 minutes for 1 cycle 











Table 2.6 Reaction mix for PCR amplification using HotStarTaq@ DNA 
Polymerase * 
Reagent Stock conc. Volume Conc.lAmt. 
DNA 100 ng/lli 1 III 100ng 
Forward primer 10 JlM 1.25 III 0.5 IlM 
Reverse primer 10 JlM 1.25 fl.1 0.5 IlM 
dNTP's (ABgene®, 
Surrey, UK) 
2.5mM 2 III 200 IlM 
10X PCR buffer (Qiagen, 
GmbH, Germany) 
10X 2.5 III 1X 
HotstarTaq® (Qiagen, GmbH, 
Germany) 
5U/volume 0.13 III 0.625U 
dH20 16.88 fl.1 
Total volume 25 III 
* Qiagen, GmbH, Germany 
The amplification reaction was carried out in a GeneAmp PCR System 9700 
(PE Applied Biosystems, USA) using the following reaction conditions: 
1) initial denaturation - 95°C I 15 minutes for 1 cycle 
2) 28 cycles: denaturation - 94°C I 30 seconds 

annealing - XoC* I 30 seconds 

elongation - 72°C I 30 seconds 

3) final step - 72°C I 5 minutes for 1 cycle 
*XoC = specific annealing temperature for each primer set 
Agarose gel electrophoresis: The PCR products were separated by 
electrophoresis on 2% (w/v) a~arose ~els. Samples were mixed with loading 












were electrophoresed in 1x Tris-acetate EDTA (TAE) running buffer (appendix 
8) and contained a molecular weight marker XIV (appendix 8) . Mini-gels (10 
cm X 7 cm) were electrophoresed in small buffer tanks at 100V for 
approximately 30 minutes. Ethidium bromide solution (10 mg/ml) (Sigma, 
Poole, England) was added to the gel and gels were visualised using a UV 
transilluminator (UVP Inc. San Gabriel, CA, USA). 
2.3.3 Single stranded conformational polymorphism (SSCP) 
The method used for SSCP analysis was based on the technique developed 
by Orita et al. (1989) with modifications to allow for non-radioactive detection 
of the single-stranded nucleic acids by silver staining (Lohmann et al. 1992). 
SSCP is based on the hypothesis that the mobility of single-stranded DNA in 
a non-denaturing polyacrylamide gel is dependent on its size as well as its 
sequence-dependent conformation. SSCP analysis of the TNF gene and 
TNFR1 gene products was carried out using a two buffer horizontal 
polyacrylamide gel electrophoresis based-system. The conformational 
changes of a single-stranded molecule induced by a polymorphism are 
sensitive to environmental influences such as the gel composition, 
temperature, ionic strength and additives such as glycerol (Liechti-Gallati et 
al. 1999). 
The protocol for this technique presents standard SSCP conditions for 
mutation screening in different genes. Liechti-Gallati et al. (1999) who 
analysed 80 known cystic fibrosis mutations and 20 polymorph isms found that 
this system was able to detect at least 97% of all point mutations in the coding 
region of the CFTR gene. In addition, they identified five novel mutations in 
this gene and detected a base substitution in a fragment larger than 500 bp. 
The Division of Human Genetics, University of Cape Town, tested this 
protocol locally by studying known sequence variations in the Rhodopsin 
(RHO) gene and confirmed the 97% sensitivity recorded in previous studies 
(Roberts et al. 1999). The defined SSCP conditions for this protocol are a 
12% nondenaturing polyacrylamide gel, 7% glycerol, two-phase buffer system 












protocol, denatured and partly re-annealed DNA fragments remain on the gel. 
This additionally allows the detection of heteroduplexes; SSCP and 
heteroduplex analysis can therefore be carried out simultaneously on the 
same gel, which increases sensitivity (Uechti-Gallati et al. 1999). The running 
temperature of the gel is easily controlled and manipulated by using a 
standard water cooler. PCR and SSCP can be carried out on 80 samples in 
less than 5 hours once optimal conditions have been determined. This 
Multiphor II system has improved the rate and sensitivity of mutation 
screening of the older SSCP techniques. In addition, visualisation is non­
radioactive and the gels are quite small (118mm X 220mm X 3mm) and easy 
to handle (Roberts et al. 1999). 
Figure 2.4 shows a typical SSCP gel using this technique. The band shifts are 
indicated on the gel (black arrows). Lane 1 shows an individual with two band 
shifts, indicated by the presence of a doublet in the single-stranded region of 
the gel and tight doublet in the double-stranded/heteroduplex region of the 
gel. In lane 2, these doublets are absent. Following this visual observation 
and confirmation, Big Dye® Terminator cycle sequencing is carried out to 

















Double stranded I 
heteroduplex region 
Figure 2.4. SSCP analysis of exon 3 of the TNFR1 gene (PCR product; 349 bp). The 
silver stained polyacrylamide gel showing band shifts in both the single and double 
stranded DNA regions, lane 1; the normal banding pattern for this exon is shown in 
lane 2. The arrows indicate the positions of the band shifts in the SSCP gel. 
As an internal study to ensure that the Multiphore II Electrophoresis system 
(Amersham Pharmacia Biotech) was working optimally for the purposes of 
this study, 66 DNA samples with 11 known mutations were obtained from the 
Wellcome Trust TB research group, Imperial College, London and were 
screened blinded. Table 2.7 summarises the PCR and SSCP conditions used 
to analyse these samples. All amplifications were preceded by a 2 minute 
denaturation step at 94°C and followed by a final elongation step at 72°C for 5 
minutes. For each PCR cycle, 94°C and 72°C were used for the denaturation 
























IFNyR1e5*1 59 Promega 28 12 
IL12R~1e14*2 59 Red Hot 28 12 
IL12R~1e15 59 Red Hot 28 12 
IL12p40e4 59 Promega 25 15 
IFNyR1e6 53 Promega 28 12 
IFNyR1e7iii 59 Promega 28 12 
IL12R~2e11 59 Red Hot + Ab 28 15 
IFNyR~2e2 59 Red Hot 28 12 
IL12R~2e5 59 Promega 26 12 
IFNyR1e1 65 Promega 25 15 
IFNyR1p1 56 Red Hot 28 12 
Examples: · 1 IFNyR1e5, Interferon gamma, receptor 1, exon 5 
.2 IL 12R~1e14, Interleukin 12, receptor ~1, exon 14 
Two microlitres of the amplification product were added to 4 III of SSCP 
loading dye (appendix C). Three microlitres of this mix was loaded onto a 
0.5mm thick, 12% non-denaturing polyacrylamide gel (appendix C). 
Electrophoresis was carried out using a Multiphor II Electrophoresis system 
(Amersham Pharmacia Biotech) at 350V for approximately 120 minutes (10­
15°C). Up to 46 samples could be run on one gel. 
Silver staining: The SSCP and heteroduplex (HD) banding patterns were 
detected by silver staining (Lohmann et al. 1992). Appendix C summarises 
the materials used for silver staining. Following gel electrophoresis, the gel is 
washed with dH20 and then covered in solution 1 (silver nitrate) and left at 
room temperature for 15 minutes. Thereafter, the gel is washed with dH20 
and then submerged in solution 2 (sodium hydroxide/formaldehyde) until the 
bands become visible. When the gel is sufficiently dark, and the bands 
intense, solution 2 is removed and the gel washed again with dH20. A sheet 
of blotting paper (Merck NT laboratory supplies (PTY) Ltd ., Fedsure Park, 
Midrand, South Africa) is placed on the gel and the gel allowed to dry. The gel 












image saved for future analysis. The gel can be stored dry for future 
reference. 
2.3.4 Sequencing analysis 
PCR products showing confirmed aberrant banding patterns following SSCP 
analyses were subjected to the Big Oye® Terminator cycle sequencing for the 
incorporation of fluorophore-Iabelled dideoxynucleotides. 
Purification of peR products: PCR products to be analysed by direct 
sequencing were purified accord ing to the protocol for the QIAquickTM PCR 
purification kit (QIAGEN, GmbH, Germany) to remove primers and dNTP's. 
DNA sequencing: A half reaction of the Big Oye® Terminator v3.1 cycle 
sequencing kit (PE Applied Biosystems, Foster City, USA) was used in the 
sequence terminator reaction mix. Table 2.8 summarises the sequencing 
reaction mix, which was made up to a final volume of 10 /-ll. 
Table 2.8 Sequence terminator reaction mix 
Reagent Volume 
Forward and reverse primers (3.2 /-lM) 1/-l1 
3-10 ng PCR product 1-5 /-ll 
Termination mix (PE Applied Biosystems, 
Foster city, USA) 
4 /-ll 
dH20 Up to 10 /-ll 
Final Volume 10 /-ll 
The amplification reaction was carried out in a GeneAmp PCR System 9700 
(PE Applied Biosystems, USA) using the following reaction conditions: 
1) initial denaturation - 96°C 110 seconds for 1 cycle 













annealing - 52°C / 15 seconds 
elongation - 60°C / 4 minutes 
3) final step - 60°C /4 minutes for 1 cycle 
The PCR products were sent to the Central DNA Sequencer at the University 
of Stellenbosch for further purification and electrophoresis on the ABI 377 
automated sequencer. All samples were sequenced in the forward and 
reverse directions using the same primers as those for PCR-SSCP analysis. 
Further analysis was performed using the NCBI BLAST search site 
(http://www.ncbLnlm.nih.gov/blastl) . The sequence data were compared to a 
reference sequence in the NCBI database and base mismatches indicated a 
single-base change. A frame-shift change, resulting from a possible deletion 
or insertion, was indicated by an unreadable sequence beyond the position of 
the insertion/deletion. The exact position of the DNA alteration was 
determined by referring to the GenBank sequence (TNF: NT _009759; TNFR1: 
NT _009731). 
2.4 GENOTYPING OF THE TNF -307 PROMOTER POLYMORPHISM 
USING ARMS-peR 
The G to A substitution at position -307 in the promoter region of TNF was 
detected by the ARMS (amplification refractory mutation system) method 
(Newton et al. 1989) that facilitates genotyping only by inspection of reaction 
mixtures after agarose gel electrophoresis. It clearly distinguishes 
heterozygotes from homozygotes for either allele at a particular locus. The 
terminal 3' nucleotide of a primer must be allele specific, the primer is 
therefore synthesised in two forms. The wild type form is refractory to PCR on 
the variant template while the variant primer is refractory to PCR on the 
wildtype template. These terminal 3' mismatches destabilise the synthesis 
end of the primer and prevent elongation. To add further to the destabilisation, 
















5' AATAGGlTlTGAGGGGCAGGG 3' and the forward primer that amplified 

the variant allele was as follows: 5' CAATAGGlTlTGAGGGGCAGGA 3'. 

Both primers were designed to have a GC+AT Tm of 64°C. The PCR cocktail 

was as per table 2.6 with the same cycling conditions listed below the table. 

When the wildtype forward primer was used, only wildtype individuals (GG) 

and well as heterozygous (GA) individuals displayed a band in the agarose 

gel. When the variant forward primer was used, only those individuals who 

were heterozygous for the polymorphism or who were homozygous variant 

(AA) displayed a band in the agarose gel. The reverse primer, 5' 

AGGGAGCGTCTGCTGGCTG 3', is the same as that used during 

amplification of part 4 of the promoter of TNF (table 2.1). Figure 2.5 illustrates 

the ARMS primers used to genotype the -307 G~A polymorphism. 

CAAAAGAAATGGAGGCAATAGGlTlTGAGGGGCATGGGGACGGGGTTC 
primer wt AATAGGlTlTGAGGGGCAGGG 
primer var CAATAGGlTlTGAGGGGCAGGA 
-307 
Figure 2.5. The ARMS primers used to genotype the -307 G~A polymorphism in 
the TNF gene. Primer wt refers to the forward primer that amplified the wildtype 
promoter sequence (-307G) while primer var refers to the forward primer that 
amplified the polymorphic promoter sequence (-307A). The introduced mismatch at 
the third base position is shown in bold type, while the terminal mismatch is 
underlined. 
2.5 GENOTYPING OF THE IL12 p40 3'UTR POLYMORPHISM USING 
RESTRICTION ENZYME ANALYSIS 
The IL 12 p40 3' UTR comprises an A~C transversion at nucl~otide position 
+1188 which creates a cutting site for Taql. A 301 bp region of this 3'UTR, 
containing this polymorphic site was amplified using the forward primer 5'­












AACATICCATACATCCTGGC-3'. The amplicons were then digested by Taq/ 
(New England Biolabs) at 65°C for 4 hours according to the manufacturer's 
instructions. Genotypes were assessed by agarose gel electrophoresis. 
Wildtype individuals (AA) displayed an undigested fragment of 301 bp, while 
carriers of the C allele presented a 162 bp and 139 bp double-band pattern in 
addition to the 301 bp fragment. 
2.6 STATISTICAL ANALYSIS 
To determine if the frequency of either of the two above-mentioned 
polymorph isms in the patient population was significantly different from the 
control population, a Chi-squared test was carried out. The Chi-test is 
calculated at a significance level of 95% i.e. a 5% probability that the null 
hypothesis (that there is no association between the polymorphism and the 
disease) is not true and 95% probability that it is true. A P-value of less than 
0.05 is generally considered to be significant. If this value is greater than 5%, 
we usually accept the null hypothesis, i.e that there is no association. In order 
to calculate this P-value for the allele numbers, a 2x2 contingency table was 
constructed, http://vassun .vassar.edu/-lowry/odds2x2.html and 
http://members.aol.com/johnp71/ctab2x2.html. In order to calculate this P­
value for the genotype numbers, a 2x3 contingency table was constructed, 
http://www.stat.sc.edu/-west/applets/contable.html. Yate's correction was 

















The 71 selected patient and control samples were analysed for sequence 
polymorph isms by SSCP analysis. Band shifts were detected upon visual 
observation. Samples were subjected to repeat PCR and SSCP-PAGE, 
followed by cycle sequencing. The results from this study are presented 
below. 
3.2 SSCP SCREENING ANALYSIS 
The internal validation study of the SSCP technique used to test DNA 
samples received from the UK collaboration resulted in ten out of eleven DNA 
polymorphisms being detected with one PCR failure. This positive outcome, 
together with published success rates of the technique (Liechti-Gallati et al. 
1999) suggested the technique to be working and suitable for the purposes of 
this study. 
TNF gene: Sequence variations in this gene were sought by screening all 4 
exons as well as the immediate 5' and 3' flanking regions. The banding 












A 1 2 3 B 1 2 c 1 2 

TfT TIC CIC GIG G/A Wt Gins. 
-1030 -1002 
Figure 3.1. SSCP gel of the TNF promoter, part 1 (-1266 to -914; 353 bp). The band 
shifts of three different sequence alterations are shown. A (-1030 T ~C): Lane 1 
represents an individual who is wildtype (TIT); lane 2, a heterozygote (TIC); lane 3, a 
homozygote (C/C) . The gel depicted here is a composite and any shifts other than 
those indicated are artefactual. B (-1 002 G~A): Lane 1 represents an individual who 
is widtype (GIG); lane 2, a heterozygote (G/A). The gel depicted here is a composite 
and any shifts other than those indicated are artefactual. C (G insertion): Lane 1 
represents an individual who is wildtype for this part of the promoter; lane 2, a 
heterozygote for a G insertion. The band shifts recorded are indicated by the black 
















Figure 3.2. SSCP gel of the TNF promoter, part 3 (-663 to -294; 370 bp). Lane 1 
represents an individual who is a heterozygote (G/A); lane 2, wildtype (GIG). The 
very tight doublet in the heteroduplex region recorded for the DNA sample in lane 1 is 
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Figure 3.3. SSCP gel of the TNF promoter, part 4 (-335 to +18; 353 bp). The band 
shifts of three different sequence alterations are shown. A (-307 G~A): Lane 1 
represents an individual who is wildtype (GIG); lane 2, a heterozygote (G/A) as 
indicated by the shadowing between the two bands; lane 3, a homozygote (NA) as 
indicated by the lack of the lower band in the single stranded region of the gel and 
the dark shadowing. B (-237 G~A): Lane 1 represents an individual who is wildtype 
(GIG); lane 2, a heterozygote (G/A) indicated by a very tight doublet. C (-76 T ~A): 
Lane 1 represents an individual who is wildtype (TIT) ; lane 2, a heterozygote (T/A) . 
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Figure 3.4. SSCP gel of the TNF promoter, part 5 (-25 to +327; 353 bp). The band 
shifts of two different sequence alterations are shown. A (+268 G~T): Lane 1 
represents an individual who is a homozygote (TIT); lane 2, a heterozygote (GIT); 
lane 3, wildtype (GIG). This alteration represents a synonymous base change in the 
codon for arginine. B (+301 C~T): Lane 1 represents an individual who is a 
heterozygote (CIT); lane 2, wildtype (C/C). This alteration represents a synonymous 
base change in the codon for isoleucine. The band shifts recorded are indicated by 















Figure 3.5. SSCP gel of the TNF exon 1 (+108 to +459; 352 bp). Lane 1 represents 
an individual who is wildtype (GIG); lane 2, a heterozygote (G/A). The band shifts 












TNFR1 gene: Sequence variations in this gene were sought by 

screening all 10 exons, as well as the immediate 5' and 3' flanking regions. 

The banding pattern and band shifts detected for this gene are shown in fig. 

3.6 to 3.11. 
A B 
1 2 1 2 




Figure 3.6. SSCP gel of the TNFR1 promoter, part 2 (-877 to -526; 352 bp). The 
band shifts of two different sequence alterations are shown. A (CT deletion): Lane 1 
represents an individual who is wildtype for this part of the promoter; lane 2, a 
heterozygote for a CT deletion. B (-610 G~T): Lane 1 represents an individual who 
is wildtype (G/G); lane 2, a heterozygote (GfT). The band shifts recorded are 












1 2 3 

AlC CIC AlA 
-383 
Figure 3.7. SSCP gel of the TNFR1 promoter, part 3 (-579 to -215; 365 bp). Lane 1 
represents an individual who is a heterozygote (AlC) ; lane 2. a homozygote (C/C); 
lane 3, wildtype (AlA). The band shifts recorded are indicated by the black arrows, 
while the dashed line indicates the wildtype band. The gel depicted here is a 















Figure 3.8. SSCP gel of the TNFR1 exon 3 (+7814 to +8161; 349 bp). Lane 1 
represents an individual who is a heterozygote (CIT) ; lane 2, wildtype (C/C). 
This alteration represents an amino acid change of a proline to leucine. The 
















Figure 3.9. SSCP gel of the TNFR1 intron 4 (+8432 to +8780; 350 bp). The band 
shifts of two different sequence alterations are shown. Lane 1 represents an 
individual who is wildtype (TIT) at position +8529 a.nd wildtype (C/C) at position 
+8634; lane 2, a heterozygote (T/G) at position +8529; lane 3, a heterozygote (CIT) 
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Figure 3.10. SSCP gel of the TNFR1 intron 6 (+10862 to +11224; 381 bp). The band 
shifts of two different sequence alterations are shown. A (+10971 A~G): Lane 1 
represents an individual who is wildtype (AlA); lane 2, a homozygote (G/G); lane 3, a 
heterozygote (AlG). B (+11040 A~G): Lane 1 represents an individual who is 
wildtype (AlA); lane 2, a heterozygote (AlG). The band shifts recorded are indicated 










A 1 2 B 
1 2 3 
CIC CIT TIT TIC CIC 
+11443 +11510 
Figure 3.11. SSCP gel of the TNFR1, intron 7 (+11201 to +11573; 373 bp). The 
band shifts of two different sequence alterations are shown. A (+11443 C-+-T): Lane 
1 represents an individual who is wildtype (C/C) ; lane 2, a heterozygote (CIT) . B 
(+11510 T -+-C): Lane 1 represents an individual who is wildtype (TIT); lane 2, a 
heterozygote (TIC); lane 3, a homozygote (C/C). The band shifts recorded are 












3.3 SEQUENCING ANALYSIS 
A total of 20 band shifts were detected by PAGE-SSCP after which 61 
samples were sequenced, each in the forward and reverse directions. This 
section gives the sequencing traces from only the novel SNP's and insertions 
or deletions detected. A homozygous base change in the DNA of a particular 
individual is indicated by a full-sized peak of a different fluorophore, while 
peak size reduction and dual fluorophores indicate heterozygosity. A deletion 
or insertion, which alters the reading frame, is indicated by an unreadable 
sequence in the sequencing trace beyond the position of the insertion or 
deletion. Figures 3.12 to 3.19 illustrate the traces obtained after sequencing of 
the novel sequence alterations. 
:30 240 ;: 
C T GG AGGGG C GGGGG T C AGG 
wildtype (-1002 GIG) 
~30 240 ;: 
C T GG AGGGG C R GGGG T C A GG 
heterozygote (-1002 G/A) 
Figure 3.12. TNF promoter, part 1 (-1266 to -914): Sections of the forward 
sequencing traces showing the -1002 G~A transition from peR products of an 
individual who is homozygous wildtype (GIG) and an individual who is heterozygous 












240 250 240 250 
GG AGGGG C GGGGG T C AGGG AG C T CC T GG AGGGG C GGGGG ICV MR GG RRS VY 
1 1 
wildtype sequence G insertion 
Figure 3.13. TNF promoter, part 1 (-1266 to -914): Sections of the forward 
sequencing traces showing the insertion of a G from PCR products of an individual 
who is wildtype and an individual who is heterozygous for a G insertion. Arrows 
indicate the position of the altered base. 
230 240 230 240 
AA GG A AG TTTT CC GC T GG AA GG AA G T TiT TT CC GC T GG 
wildtype (-76 TIT) heterozygote (-76 T/A) 
Figure 3.14. TNF promoter, part 4 (-335 to +18) : Sections of the forward sequencing 
traces showing the -76 T~A transition from the PCR products of an individual who is 
wildtype (TfT) and an individual who is heterozygous (T/A). Arrows indicate the 











290 300 300 310 
I I C I C C T T C C T G A T C G T G G C TT C TCC TT CC T G AT YG TGG C AGG C 
wildtype (C/C) heterozygote (+301 CfT) 
Figure 3.15. TNF promoter, part 5 (-25 to +327): Sections of the forward sequencing 
traces showing the +301 C-)oT transition from the PCR products of an individual who 
is wildtype (C/C) and an individual who is heterozygous (CIT). Arrows indicate the 
position of the altered base. This alteration represents a synonymous base change in 
the codon for isoleucine. 
80 90 100 30 90 100 
CTA GTGH GH CTCT GG AGH U GGGG AGG CH GTGH GH CTSI< GGQRC ARGGG RGRR 
CT deletion (-759/760) wildtype sequence 
Figure 3.16. TNFR1 promoter, part 2 (-877 to -526): Sections of the forward 
sequencing traces showing the -759/760 CT deletion from the PCR products of an 
individual who is wildtype and an individual who is heterozygous for a CT deletion. 











150 16( 150 16 
AT CCC ACCC AT CC AT C T AT AT CCC ACCC R T CC AT C T AT 
wildtype (NA) heterozygote (+11040 NG) 
Figure 3.17. TNFR1, intron 6 (+10862 to +11224): Sections of the forward 
sequencing traces showing the +11040 A~G transition from the PCR products of an 
individual who is wildtype (AlA) and an individual who is heterozygous (AlG). Arrows 
indicate the position of the altered base. 
210 220 220 231 
C A C A A G T C C C C AC T G C C fA C A C A fA G T C C C Y AC T G C C A 
1 
wildtype (C/C) heterozygote (+11443 CIT) 
Figure 3.18. TNFR1, intron 7 (+11201 to +11573) : Sections of the forward 
sequencing traces showing the +11443 C~T transition from the PCR products of an 
individual who is wildtype (C/C) and an individual who is heterozygous (CIT). Arrows 












280 290 280 290 ~80 290 
TC TTT C TTTTT CC T C A TC TTTC TT YTTCC TC A TC TTT C TT C TT CC T C A 
1 1 
A 
wildtype (Trr) heterozygote (+11510 TIC) homozygote (+11510 C/C) 
Figure 3.19. TNFR1, intron 7 (+11201 to +11573): Sections of the forward 
sequencing traces showing the T ~C transition from the PCR products from an 
individual who is wildtype (TfT) , an individual who is heterozygous (TIC) and an 
individual who is homozygous (C/C) . Arrows indicate the position of the altered base. 














Promoter Exon 1 Exon 2 Exon 3 Exon 4 
Figure 3.20. Summary diagram of the sequence alterations in the TNF gene 











Figure 3.21 illustrates the positions of the TNF promoter polymorph isms 
































Figure 3.21. Promoter sequence of the TNF gene. The letters indicated in red and 
labelled with a position number refer to the DNA alterations detected in this study. 
The underlined sequences indicate consensus sequences for transcription factors, 
Sp1 in which the -1002 polymorphism is found and Ap2, in which the -307 












Figure 3.22 summarises all the polymorph isms identified in the TNFR1 gene 
in this study. 
AlG +10971 
CT del. -759/760* AlG +11040* 
GIT --610 
CIT +11443* 
AlC -383 T/G +8529 
T/C+11510* 
CIT +8634 
Promoter E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 
Figure 3.22. Summary diagram of the sequence alterations in the TNFR1 gene 













Figure 3.23 illustrates the positions of the TNFR1 promoter polymorphisms 
























Figure 3.23. Promoter sequence of the TNFR1 gene. The letters indicated in red and 
labelled with a position number refer to the DNA alterations detected in this study. 
In order to determine if any of the polymorphisms identified in this study were 
associated with high or low TNF levels, allele frequencies had to be compared 
between high and low TNF producers. The following table summarises the 
frequencies of the polymorph isms detected in the high and low producers of 
TNF and their P-values. There was no functional in vitro evaluation of TNFR1 












Table 3.1 Allele frequencies of the TNF and TNFR1 gene polymorphisms 
detected in this study compared to TNF production 
Polymorphism Frequency in 
high TNF 
producers 
Frequency in low 
TNF producers 
P-value 































Allele numbers were compared IJsing Chi-squared analysis. A P-value of less 
than 0.05 was considered to be statistically significant. Yate's correction was 
applied for small numbers. There does not appear to be any association 
between any of the above polymorph isms and TNF production. The other 
polymorph isms that do not feature in this table have sample sizes that are too 
small to calculate a P-value. A much larger study would need to be carried out 
to evaluate any association between TNF production and these rare 
polymorph isms. 
3.4 GENOTYPING OF THE TNF -307 PROMOTER POLYMORPHISM 
The G to A substitution at position -307 in the promoter region of TNF was 












homozygotes for either allele at a particular locus. Individuals who are 
amplified with the wildtype primer are shown in fig. 3.24, lanes 1, 3 and 5. 
Individuals who are amplified with the variant primer are shown in fig. 3.24, 
lanes 2, 4 and 6. 
M 1 2 3 4 5 6 
Lanes 1, 3, 5: wildtype ARMS 
primer (G allele) 
Lanes 2, 4, 6: variant ARMS 
primer (A allele) 
Figure 3.24. Genotyping of the -307 G~A polymorphism in the TNF promoter. A 2% 
(w/v) agarose gel showing a homozygote for the G allele (lanes 1+2), a heterozygote 
G/A (lanes 3+4) and a homozygote for the A allele (lanes 5+6). Lane M is the marker 
XIV (appendix B). 
Over 500 childhood patients and controls were recruited and immuno­
phenotyped as part of this multi-centre study, after which the DNA was 
extracted. Most of these subjects come from disadvantaged areas where TB 
infection is widespread. Due to sample degradation and volume limitation, 
only 276 individuals were genotyped for the TNF -307 G-4A polymorphism. 
The demographics of the patient and control groups for this polymorphism are 
shown in table 3.2. All the observed frequencies were in Hardy-Weinberg 
equilibrium, which means that neither of the two loci is under selective 
pressure; the proportions of homozygotes and heterozygotes in each 











Table 3.2 Genotype and allele frequencies in patients and controls for the 
-307 G~A polymorphism in the TNF promoter 
Genotype and allele frequency Healthy controls Patients 
(N=128) (N=148) 
GG 95 (0.74) 109 (0.74) 
GA 31 (0.24) 35 (0.23) 
AA 2 (0.02) 4 (0.03) 
G/A 0.86/0.14 0.85/0.15 
Allele and genotype numbers were compared using Chi-squared analysis. A 
P-value of less than 0.05 was considered to be statistically significant. There 
were no significant differences in the distribution of this polymorphism 
between the patient and control subjects when allele numbers (P=0.8) and 
when genotype numbers (P=0.8) were compared. Yate's correction was 
applied (Yate's Chi2 = 0.027; degrees of freedom = 1). 
3.5 GENOTYPING OF THE IL12 p40 3'UTR POLYMORPHISM 
Two hundred and eighty one patient and control samples were genotyped for 
the IL 12 +1188 A~C polymorphism. Genotyping of the patient and control 
cohorts for this polymorphism was carried out by restriction enzyme analysis 
using the Taql restriction enzyme. The digestion products were 
electrophoresed on 4% (w/v) agarose gels. An uncut fragment appears as a 

















Figure 3.25. Genotyping of the +1188 A~C polymorphism in the IL12 3'UTR. A 4% 

(w/v) agarose gel showing hetrozygotes for the IL 12 p40 polymorphism 

(lanes, 1, 2, 4 and 5), a homozygote for the C allele (lane 3) and a homozygote for 

the A allele (lane 6). Lane M is the marker XIV (appendix B). 

The demographics of the patient and control groups are shown in table 3.3. 
All the observed frequencies were in Hardy-Weinberg equilibrium. 
Table 3.3 Genotype and allele frequencies in patients and controls for the 
IL 12 +1188 A~C polymorphism 

















Allele and genotype numbers were compared using Chi-squared analysis. A 
P-value of less than 0.05 was considered to be statistically significant. There 












between the patient and control subjects when allele numbers (P=0.3) and 
when genotype numbers were compared (P=0.2). Yate's correction was 
















Mycobacterium tuberculosis infection is characterised by diverse outcomes; 
the majority of infected individuals remain well while others develop disease 
ranging from limited pulmonary tuberculosis to severe disseminated disease. 
Host factors are indicated to play an important role in these diverse outcomes, 
a role which has yet to be fully characterised. Genetic components of 
susceptibility to tuberculosis have been proposed with elements of the type 1 
cytokine pathways being investigated. Players in these pathways include 
interferon gamma, interleukin-12, their receptors, and TNF and its receptor. 
TNF gene polymorph isms have been implicated in the pathogenesis of a 
number of diseases, infectious and autoimmune, such as cerebral malaria 
(McGuire et al. 1994; Knight et al. 1999) and rheumatoid arthritis (Kaijzel et al. 
2001). Given the strong evidence supporting a role for TNF in mediating 
protection and pathology in TB, from both murine models and human disease, 
it seemed appropriate to study our TB cohort for polymorph isms in the TNF 
gene and its receptor. 
In an attempt to determine the specific influence of genetic variability in the 
TNF and TNFR1 genes, this thesis focussed initially on a limited group of 
patients and controls, selected on the basis of whole blood TNF synthesis in 
response to non-specific stimulation tests. DNA samples from this selected 
cohort were screened for polymorphisms by SSCP analysis and cycle 
sequencing. In subsequent investigations a much larger cohort of TB patients 
and controls were screened for the frequencies of a polymorphism identified 
in this study, the TNF -307 G-"7A polymorphism, and an IL 12 3'UTR A-"7C 
polymorphism, in order to evaluate any possible association with paediatric 
tuberculosis. 
This study reports the identification of ten polymorph isms in the TNF gene 












The six polymorph isms found in the TNF promoter, comprise five single 
nucleotide sUbstitutions and a single G insertion in a run of five G's. For the 
remainder, two were found in exon 1 and one in intron 1. Three 
polymorph isms were detected in the TNFR1 promoter, two of these being 
single nucleotide substitutions with the third being a dinucleotide deletion. For 
the remainder, most were intronic, two each in introns 4, 6 and 7. Only one 
exonic SNP was found in the TNFR1 gene. 
Eight novel polymorph isms were identified. These were the TNF -1002 G~A 
(AY799803), G insertion (AY799804), -76 T~A (AY799805), and +301 C~T 
(AY799806) promoter and exon polymorph isms, respectively. For TNFR1 
there was the dinucleotide promoter deletion, -7591760 CT (AY799807), and 
the intronic SNP's, +11040 A~G (AY799808), +11443 C~T (AY799809) and 
+11510 T ~C (AY79981 0). The numbers in brackets refer to the GenBank 
numbers for these polymorphisms. PCR, SSCP and sequencing analysis 
were carried out twice on samples carrying these novel alterations to ensure 
that the changes were not the result of PCR or sequencing artefacts. 
While this study only detected six polymorphisms in the TNF promoter, it is of 
interest that 11 are now known,' and indicate a high degree of heterogeneity. 
There exists some confusion as regards the numbering of several of these 
polymorph isms, which has its roots in the miss-numbering of the original TNF 
promoter sequence. For example, what has previously been referred to as the 
TNF -308 polymorphism is actually 307 base pairs upstream of the 
transcription start site (Allen 1999). 
Do these polymorphisms have functional significance? 
Most studies that have investigated the functional significance of TNF 
promoter polymorph isms have focused on the -307 polymorphism, although 
the results are highly contradictory. Two studies that looked at the in vitro 
stimulation of TNF production by leukocytes from homozygous wild type (-307 
GIG) and heterozygous (-307 G/A) individuals reported higher TNF production 












significant effect, in similar investigations. The conflicting data from these six 
studies may be due to the use of different LPS concentrations in each as well 
as the small number of individuals with the -307 G/A genotype studied. This 
polymorphism has also been investigated by gene reporter assays, again with 
conflicting results; three reports of the -307A allele having an influence on 
TNF gene transcription and three reports of it not. Reasons given for the 
contradictions in these studies as well as in other reporter gene approaches 
include the use of different promoter regions, the type of cell used for 
transfection and the absence or presence of the 3'UTR. However, collectively 
the studies suggest that the -307A allele is associated with higher, and not 
lower, TNF gene expression (Allen 1999; Hajeer and Hutchinson 2001). In 
addition, the -307A allele is in linkage disequilibrium with the HLA-DR3 allele 
which has been associated with high TNF production, however the high TNF 
production associated with this DR3 allele may be due to its association with 
the -307A allele rather than the DR3 allele being responsible for higher TNF 
production (Allen 1999). 
Studies that have investigated other TNF polymorphisms for an effect on gene 
transcription have also had contradictory results. One study on the TNF -237 
G~A polymorphism has reported lower TNF production from LPS stimulation 
of whole blood from -237 G/A individuals than from -237 GIG individuals, 
while another study showed no difference. The TNF -375 G~A and -237 
G~A polymorph isms have been shown to have no effect on transcriptional 
activity using a reporter gene assay (Allen 1999). The -375 G~A 
polymorphism has also been shown to be situated in a region of multiple 
DNA-protein interactions where the -376 A allele recruits OCT -1 to this region 
(Knight et al. 1999). In addition, there is support for linkage disequilibrium in 
this region of the promoter. In Caucasians, for example, the -375 A allele is in 
allelic association with the -307 G and -237 A alleles. A strong allelic 
association has also been shown between -237 G, -307 A and -375 G, and 
this association has been found to encode high TNF production in vitro 












The novel TNF -1002 G~A polymorphism occurs within the binding site for 
the transcription factor Sp1. It has been suggested that Sp1 may be involved 
in bringing distally bound proteins into the presence of the proximal promoter 
through DNA looping (Eichbaum et al. 1997). The TNF -307 G~A 
polymorphism occurs within a consensus sequence for an Ap2 transcription 
factor. However, the actual binding of Ap2 to this promoter element has not 
been shown (Wilson et al. 1997). 
The TNFR1 promoter is not well characterised and resembles that of a 
housekeeping gene. The -7591760 CT deletion identified in the TNFR1 
promoter is interesting as it occurs in a region that is thought to contain a 
negative putative regulatory element. The sequence upstream from -385, 
until the start of the promoter at position -809, has an inhibitory effect on 
promoter activity in reporter gene assays (Kemper and Wallach 1993). It may 
be significant that the CT deletion as well as the TNFR1 -61 0 G~T 
polymorphism are located in this region and either could possibly influence 
the inhibitory property of this region. Promoter activity has been localised to a 
CT -rich region running from bases -207 to -385 and again, it may be of 
significance that the TNFR1 -383 A~C polymorphism is situated in this 
region. Therefore, this -383 A~C polymorphism could increase TNFR1 
expression as was confirmed by Nishimura et al. (2003) who observed a 
significantly increased frequency of the -383 C allele in young-onset (25.6% 
heterozygotes) (P= 0.0056) and adult-onset diabetes (24% heterozygotes) 
(P=O.015) patients when compared with controls (11% heterozygotes). The 
TNFR1 + 7979 C~T polymorphism resulted in the substitution of proline for 
leucine in exon 3. Sequence variants that involve the removal of proline 
residues likely remove a distinct kink in the polypeptide chain and likely have 
an effect on the secondary and possibly tertiary structure of the protein. 
Are the polymorph isms identified in this study associated with high or 
low TNF production? 
It is important to evaluate the ability of DNA variants to influence TNF 












-1030 T~C, -307 G~A and +268 G~T as well as the TNFR1 -383 A~C , 
+10971 A~G and +11510 T ~C (AY79981 0) polymorph isms were examined 
by Chi- squared analysis for a possible association with TNF expression. The 
study cohort comprised 71 individuals with .28 subjects having high TNF levels 
and the other 43 with low TNF levels, on whole blood stimulation. The 
polymorph isms mentioned above were the only ones that had sufficiently 
large enough sample sizes to evaluate. Less frequent polymorph isms 
identified in this study will need to be evaluated in the larger cohort. P-values 
calculated for the above polymorph isms failed to detect any significant 
association with high or low TNF production. However, it is interesting to note 
that two polymorph isms were only present in individuals with low TNF 
production, namely the TNF +301 C~T (AY799806) polymorphism and the 
TNF +421 G~A polymorphism although the number of individuals presenting 
with these two polymorphisms was very small «5 individuals out of 71 for 
each polymorphism). These interesting leads warrant further investigation. 
Association of the TNF -307 G~A and the IL12 +1188 A~C 
polymorphism with M. tuberculosis infection 
Major genes have been effectively found by linkage analysis; however these 
studies have limited power to detect modest gene effects. Direct tests of 
association with a candidate gene locus are more powerful at detecting 
modest gene effects and this approach has been used extensively with 
respect to genetic variation at the TNF locus, although familial inheritance 
patterns are not indicated in association studies. A large number of studies 
evaluating associations of TNF polymorphisms with a particular disease have 
found that apparent associations between TNF alterations and disease were 
confounded by linkage disequilibrium between TNF and HLA markers. 
Linkage disequilibrium also exists within the TNF locus. Association studies 
for this region frequently have a small sample size with insufficient power to 
detect a significant difference (Knight and Kwiatkowski 1999). In the broader 
context of mapping disease loci, linkage analysis is more powerful for the 
detection of high-risk alleles than association studies. Association analysis is 












modest disease risks. It is easier to recruit large numbers of unrelated 
affected individuals for association studies than to recruit large numbers of 
pedigrees with multiple affected individuals, however, the region around a 
SNP that is shared in unrelated affected individuals is much smaller than the 
shared region for related individuals. Therefore, in order to be successful in 
mapping loci through association studies, much higher SNP densities are 
needed (Carlson et a!. 2004). 
This thesis selected two of the more interesting polymorphisms for an 
investigation of possible association with M. tuberculosis infection. These 
were the TNF -307 G~A polymorphism and the IL12 +1188 A~C 
polymorphisms. At a significance level of 5%, there were no differences in the 
distribution of these two polymorph isms between the TB patient and control 
groups. The frequencies of the TNF -307G allele in the patient and control 
groups were 0.85 and 0.86 respectively. The frequencies of the TNF -307 A 
allele in the patient and control groups were 0.15 and 0.14 respectively. 
These frequencies correlate with those obtained in previous studies of other 
disorders (Chen et al. 1997; Patuzzo et al. 2000). The frequencies of the IL12 
A allele in the patient and control groups were 0.71 and 0.66 respectively. 
The frequencies of the IL12 C allele in the patient and control groups were 
0.29 and 0.34 respectively. These frequencies correlate with those obtained 
in a previous study of type 1 diabetes (Morahan et al. 2001). A factor that 
could have impacted on these results is the difficulty in obtaining an 
appropriate control group for association studies in paediatric TB, which is a 
problem due to the age spectrum of infection. An individual who at the time of 
this study appeared to be an unaffected control could still go on to develop TB 
at a later stage in life. This is particularly problematic when selecting 
childhood controls, since tuberculin skin test-positive healthy children 
(selected on the basis that they have encountered TB and yet remained 













The methods employed in this study were effective in detecting a number of 
polymorph isms, however they are not without their limitations. Factors that 
could affect the sensitivity of SSCP analysis include the nature of the 
mutation, the sequence composition of the DNA fragment, the position of the 
mutation within the amplification product and the influence of the neighbouring 
bases. There is no theoretical model in SSCP for predicting the three­
dimensional structure or mobility shift of single-stranded DNA under given 
conditions (Liechti-Gal/ati et al. 1999). The mobility shifted bands detected in 
this study varied from one to three in a single sample. The major banding 
patterns seen in the SSCP gels varied from two to five. This is due to the fact 
that both single and heteroduplex forms of the PCR products are seen on the 
same gel. Sequence alterations were found to affect both DNA conformers, 
most often individually but on occasion, band shifts were seen in both regions 
of the gel. In addition, the number of alterations found in this study is likely to 
be an underestimate of the changes in the cohort as the SSCP technique 
used is not 100% sensitive. 
Another significant limitation in this study was the sample size screened for 
polymorph isms and more specifically, the sample sizes for the high and low 
TNF production groups. Time constraints as well as sample availability played 
a role in the choice of these sample sizes. The assumption here was that the 
selected cohort (n=71) would be enriched for polymorphisms impacting on 
TNF gene and protein expression and would be large enough to uncover 
polymorphisms of major biological importance in the South African population. 
It is likely that very rare polymorphisms or mutations were not detected as a 
result. Financial constraints prohibited the sequencing of all samples 
presenting with a band shift different to the wild type , therefore only 
representative samples were sequenced. As a result, additional 
polymorphisms to those identified may have been missed as one banding 
pattern may have represented two different polymorphisms, although this 












Conclusions I future work 
In spite of the limitations mentioned above, 20 polymorph isms were identified 
in the TNF and TNFR1 genes, of which 4 in each gene were novel. What was 
also interesting to note was that almost half of the individuals investigated 
presented with a number of different polymorphisms, with one individual being 
heterozygous for eight of the rare alleles at the polymorphic loci identified in 
the two genes, while others were wild type at the loci identified. This suggests 
that in the African population the TNF and TNFR1 genes may be highly 
polymorphic and that perhaps it is the presence, or lack, of a number of these 
polymorphisms occurring together in a particular individual that predisposes 
him/her to tuberculosis infection. 
In order to detect very rare polymorphisms, or in other words mutations, it is 
necessary to extend this study to the whole cohort. The whole paediatric TB 
cohort, consisting of over 500 patient and control samples, at the Red Cross 
Children's Hospital will need to be screened for polymorphisms in the TNF 
and TNFR1 genes. In addition, the allele frequencies of these polymorph isms 
can then be compared between the control and patient groups in order to 
make any conclusions about possible association with TB disease. Functional 
assays like those mentioned in other studies that employ reporter gene 
constructs could be carried out to determine any possible functional 
significance of these polymorphisms. In addition, further investigation of the 
novel changes, such as the CT deletion in the TNFR1 promoter, is necessary 
to understand their relevance to TB. 
In conclusion, although the current thesis did not identify polymorph isms with 
any obvious association with either tuberculosis or TNF production, a number 
of novel polymorph isms were identified. These may interact with other loci to 
affect TNF responses and perhaps predispose to tuberculosis. The challenge 
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Appendix A: Primer troubleshooting 
2.5.1 Tris-borate EDTA buffer (SOx) 
108g (0.89M) Tris (lCN Biomedicals Inc., Aurora, Ohio, USA) 
55g (0.89M) Boric acid (lCN Biomedicals Inc., Aurora, Ohio, USA) 
7.4g (0.02M) EDTA, pH 8.0 (BDH Laboratory supplies, Poole, England) 
Make up to 1000ml with dH20 
2.5.2 Sequencing gel (10%) 
25 ml (30% w/v) acrylamide (BDH Laboratory supplies, Poole, England) 
15 ml Tris Borate EDTA 
31.5g Urea (Promega, Madison, WI, USA) 

Add dH20 to 75ml 

Add 300 J.1110% APS (BDH Laboratory supplies, Poole, England) 

Add 80 J.11 TEMED (Promega, Madison, WI, USA) 

2.5.3 Silver staining solutions 
Fixer solution: 150ml Ethanol (Merck KgaA, Darmstadt, Germany) 
15ml Acetic acid (Merck KgaA, Darmstadt, Germany) 
Add dH20 to 1000ml 
Pre-treatment solution: 22.5ml Nitric acid (Fluka chemika, Buchs, 
Switzerland) 
Add dH20 to 1500 ml 
Silver solution: 3g Silver nitrate (Merck NT laboratory supplies (PTY) 
Ltd., Fedsure Park, Midrand. South Africa) 
Add dH20 to 1500ml 
Developer: 45g Sodium carbonate (Merck KgaA. Darmstadt, Germany) 
0.81mI37% formaldehyde solution 











Appendix B: agarose gel formulas 

2.6.1 Agarose (Agarose, Roche Diagnostics, GmbH Mannheim, 
Germany) gel loading dye (6x) 
0.25g (0.25% w/v) Bromophenol Blue (Merck KgaA, Darmstadt, 
Germany) 
40g (40% w/v) sucrose (Merck chemicals and laboratory supplies (Pty) 
Ltd., Gauteng, SA) 
4ml (20mM) EDTA, pH 8.0 (BDH Laboratory supplies, Poole, England) 
Make up to 100ml with dH20 
Store at 4°C 
2.6.2 Tris-acetate EDT A buffer (SOx) 
242g Tris (Merck KgaA, Darmstadt, Germany) 
57.1 ml glacial acetic acid (Merck KgaA, Darmstadt, Germany) 
100ml 0.5M EDTA, pH 8.0 (BDH Laboratory supplies, Poole, England) 
Make up to 1000ml with dH20 
2.6.3 Marker XIV 
2,.d of agarose loading dye and 3J.11 dH20 was added to 3,.11 of marker 















Appendix C: SSCP and silver stain formulas 
2.7.1 Acrylamide-piperazine diacrylamide (PDA) solution (40%; 99:1) 
396g acrylamide (BDH laboratory supplies, Poole, England) 
4g PDA (Bio-rad laboratories, Hercules, CA, USA) 
Make up to 1000ml with dH20 
2.7.2 Tris-formate buffer (0.7SM) 
90.8g Tris (Merck KgaA, Darmstadt, Germany) 
Make up to 1000 ml with dH20, pH to 9.0 with formic acid (Merck KgaA, 
Darmstadt, Germany) 
2.7.3 Tris-borate buffer (SOx) 
125.9g Tris (Merck KgaA, Darmstadt, Germany) 

17.3g Boric acid (Merck KgaA, Darmstadt, Germany) 

Dissolve in 950ml dH20, pH to 9.0. 





2.7.4 Glycerol stock (41%) 
41 ml glycerol (Saarchem (Pty) Ltd. Muldersdrift, South Africa) 
59ml dH20 
2.7.5 SSCP loading dye 
47.5 rnl (95%) formam ide (RdH Laborchemikalien, GmbH and Co.) 

0.16g (100mM) NaOH (Merck NT laboratory supplies (PTY) Ltd. 

Fedsure Park, Midrand, South Africa) 





















2.7.6 Non~denaturing polyacrylamide gel (12%) 
5.3ml 40% acrylamide-POA solution 
8.5ml Tris-formate buffer 
3ml 41 % glycerol (Saarchem (pty) Ltd. Muldersdrift, South Africa) 
Add 200 ,..,,1 APS (SOH Laboratory supplies, Poole, England) 
Add 20,..,,1 TEMEO (Promega, Madison, WI, USA) 
2.7.7 Silver staining solutions 
Solution 1: 19 (0.1% w/v) silver nitrate (Merck NT laboratory supplies (PTY) 
Ltd., Fedsure Park, Midrand, South Africa) 
Add dH20 to 1000 ml 
Solution 2: 15g (1.5% w/v) NaOH pellets (SOH laboratory supplies, Poole, 
England) 
10ml (0.15%) formaldehyde (SOH laboratory supplies, Poole, 
England) 
Add dH20 to 1000 ml 
100 

